514 Rec'd PCT/PTO 1 4 MAR 2000 09/508658

Practitioner's Docket No. <u>U 012653-9</u>

CHAPTER II

TRANSMITTAL LETTER TO THE UNITED STATES ELECTED OFFICE (EO/US)

(ENTRY INTO U.S. NATIONAL PHASE UNDER CHAPTER II)

PCT/FI98/00749
23 SEPT. 1998
23 SEPT. 1997
INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE
CLAIMED

NOVEL GENE DEFECTIVE IN APECED AND ITS USE
TITLE OF INVENTION

Kai KROHN; Maarit HEINO; Part PETERSON; Hamish SCOTT; Stylianos ANTONARAKIS; Maria LALIOTI; Nobuyoshi SHIMIZU; Jan KUDOH

APPLICANT(S)

Box PCT
Assistant Commissioner for Patents
Washington D.C. 20231
ATTENTION: EO/US

NOTE: The completion of those filing requirements that can be made at a time later than 30 months from the priority date results from the Commissioner exercising his judgment under the authority granted under 35 USC 371(d). The filing receipt will show the actual date of receipt of the last item completing the entry into the national phase. See 37 C.F.R. §1.491 which states: "An international application enters the national state when the applicant has filed the documents and fees required by 35 USC 371(c) within the periods set forth in § 1.494 and § 1.495."

CERTIFICATION UNDER 37 C.F.R. 1.10*

(Express Mail label number is **mandatory**.) (Express Mail certification is optional.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on this date <u>MARCH 14, 2000</u>, in an envelope as "Express Mail Post Office to Addressee," Mailing Label Number <u>EL386267956US</u>, addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

JENNIFER RASHKIN

(type or print name of person mailing paper)

Signature of person mailing paper

WARNING:

Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

*WARNING:

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement

will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Transmittal Letter to the United States Elected Office (EO/US)—page 1 of 8)

09/508658 428 Recid PCT/PTO 14 MAR 2000

WARNING:

Where the items are those which can be submitted to complete the entry of the international application into the national phase are subsequent to 30 months from the priority date the application is still considered to be in the international state and if mailing procedures are utilized to obtain a date the express mail procedure of 37 C.F.R. §1.10 must be used (since international application papers are not covered by an ordinary certificate of mailing - See 37 C.F.R. §1.8.

NOTE: Documents and fees must be clearly identified as a submission to enter the national state under 35 USC 371 otherwise the submission will be considered as being made under 35 USC 111. 37 C.F.R. § 1.494(f).

- 1. Applicant herewith submits to the United States Elected Office (EO/US) the following items under 35 U.S.C. 371:
 - a. [x] This express request to immediately begin national examination procedures (35 U.S.C. 371(f)).
 - b. [x] The U.S. National Fee (35 U.S.C. 371(c)(1)) and other fees (37 C.F.R. § 1.492) as indicated below:

09/508658 428 Recid PCT/PTO 14 MAR 2000

2.Fees

CLAIMS	(1) FOR	(2) NUMBER	(3) NUMBER	(4) RATE	(5) CALCULA-
FEE		FILED	EXTRA		TIONS
[]*	TOTAL CLAIMS	24 - 20 =	4	x \$18.00 =	\$72.00
	INDEPENDENT CLAIMS	78.00			
	MULTIPLE DEPE	NDENT CLAIM(S) (it			
BASIC FEE**	[] U.S. PTO AUTHOR Where ar 1.482 has [] [] [] [X] U.S. PTO EXAMIN Where no in § 1.482	O WAS INTERNATION RITY In International preliming been paid on the international preliming the criteria of novelty, industrial activity, as of been satisfied for all the entering the national sand the above requirer	NAL PRELIMINARY ary examination fee as national application to oreliminary examination inventive step (non-oldefined in PCT Article ac claims presented in tage (37 CFR 1.492(a)) ments are not met (37 CATIONAL PRELIMIN ATIONAL PRELIMIN (ary examination fee as J.S. PTO, and payment the in § 1.445(a)(2) to the claim of the international appean Patent Office or the	EXAMINATION set forth in § the U.S. PTO: n report states that oviousness) and 33(2) to (4) have the application (4))	\$970.00
			Total of a	bove Calculations	=\$1,120.00
SMALL ENTITY	Reduction by ½ for (note 37 CFR 1.9, 1	filing by small entity, .27, 1.28)	if applicable. Affidavit	must be filed.	-
				Subtotal	
			Т	otal National Fee	\$
	Fee for recording the (See Item 13 below)				
TOTAL			To	otal Fees enclosed	\$1,120.00

^{*}See attached Preliminary Amendment Reducing the Number of Claims.

09/508658 428 Rec'd PCT/PTO 1 4 MAR 2000

	1.		A check in the amount of $$1,120.00$ to cover the above fees is enclosed.										
	ii.	[]	Please charge Account No in the amount of \$										
		A duplicate copy of this sheet is enclosed.											
WAR	NING:	Iradem	"To avoid abandonment of the application the applicant shall furnish to the United States Patent and Trademark Office not later than the expiration of 30 months from the priority date: $*(2)$ the basic national fee (see § 1.492(a)) The 30-month time limit may not be extended." 37 C.F.R. § 1.495(b).										
WARNING:		submitte met with forth in months accepta comply	If the translation of the international application and/or the oath or declaration have not been submitted by the applicant within thirty (30) months from the priority date, such requirements may be met within a time period set by the Office. 37 C.F.R. § $1.495(b)(2)$. The payment of the surcharge set forth in § $1.492(e)$ is required as a condition for accepting the oath or declaration later than thirty (30) months after the priority date. The payment of the processing fee set forth in § $1.492(f)$ is required for acceptance of an English translation later than thirty (30) months after the priority date. Failure to comply with these requirements will result in abandonment of the application. The provisions of § 1.136 apply to the period which is set. Notice of Jan. 3, 1993 , 1147 O.G. 29 to 40.										
3.	[X]	A copy	y of the International application as filed (35 U.S.C. 371(c)(2)):										
NOTE:	must be Bureau 20. At the accorda the common normally	filed with normally p ne same tin nce with l municatio v need onl tional fee	was amended to require that the basic national fee and a copy of the international application the Office by 30 months from the priority date to avoid abandonment "The International provides the copy of the international application to the Office in accordance with PCT Article me, the International Bureau notifies applicant of the communication to the Office. In PCT Rule 47.1, that notice shall be accepted by all designated offices as conclusive evidence that in has duly taken place. Thus, if the applicant desires to enter the national stage, the applicant ly check to be sure the notice from the International Bureau has been received and then pay the by 30 months from the priority date." Notice of Jan. 7, 1993, 1147 O.G. 29 to 40, at 35-36. See										
	a.	[]	is transmitted herewith.										
	b.	Ĺĺ	is not required, as the application was filed with the United States Receiving Office.										
	c.	[X] has been transmitted											
		i.	[X] by the International Bureau.										
			Date of mailing of the application (from form PCT/IB/308): APRIL 1, 1999.										
		ii.	[] by applicant on Date										
4.	[X]	A trans	slation of the International application into the English language (35 U.S.C. (2)):										
	a.	[X] ·	is transmitted herewith.										
	b.	[]	is not required as the application was filed in English.										
	c.	[] was previously transmitted by applicant on											
	d.	[]	will follow.										

09/508658 428 Rec'd PCT/PTO 14 MAR 2000

5.	[X]	Amen U.S.C	dments to the claims of the International application under PCT Article 19 (35 . 371(c)(3)):
NOTE:	conting this de the sub amend	uing praction adline may Dject matter Tiled 1	uary 7, 1993 points out that 37 C.F.R. § 1.495(a) was amended to clarify the existing and ce that PCT Article 19 amendments must be submitted by 30 months from the priority date and not be extended. The Notice further advises that: "The failure to do so will not result in loss of of the PCT Article 19 amendments. Applicant may submit that subject matter in a preliminary under section 1.121. In many cases, filing an amendment under section 1.121 is preferable since the corrected." 1147 O.G. 29-40, at 36.
	a.	[]	are transmitted herewith.
	b.	į į	have been transmitted
		i.	[] by the International Bureau.
			Date of mailing of the amendment (from form PCT/IB/308):
		ii.	by applicant on
		LXJ	Date
	c.	[X] i.	have not been transmitted as [X] applicant chose not to make amendments under PCT Article 19.
		1.	[X] applicant chose not to make amendments under PCT Article 19. Date of mailing of Search Report (from form PCT/ISA/210): JAN. 25, 1999.
		ii.	[] the time limit for the submission of amendments has not yet expired The amendments or a statement that amendments have not been made will be transmitted before the expiration of the time limit unde PCT Rule 46.1.
6.	[X]	A trans	slation of the amendments to the claims under PCT Article 19 (38 U.S.C. (3)):
	a.	[]	is transmitted herewith.
	b. c.	[] [X]	is not required as the amendments were made in the English language. has not been transmitted for reasons indicated at point 5(c) above.
7.	[X]	А сору [X]	of the international examination report (PCT/IPEA/409) is transmitted herewith.
			is not required as the application was filed with the United States Receiving Office.
8.	[X]	Annex	(es) to the international preliminary examination report
	a.	[X]	is/are transmitted herewith.
	b.	[]	is/are not required as the application was filed with the United States Receiving Office.
9.	[X] a.	A trans	slation of the annexes to the international preliminary examination report is transmitted herewith.
	b.	ĺΧΊ	is not required as the annexes are in the English language

09/508658 428 Rec'd PCT/PTO 14 MAR 2000

10.	[X]	An oa U.S.C	ath or declaration of the inventor (35 U.S.C. 371(c)(4)) complying with 35 C. 115
	a.	[]	was previously submitted by applicant on
	b. с.	[] i. ii.	is submitted herewith, and such oath or declaration [] is attached to the application. [] identifies the application and any amendments under PCT Article 1 that were transmitted as stated in points 3(b) or 3(c) and 5(b); and states that they were reviewed by the inventor as required by 37 C.F.R. 1.70. [X] will follow.
0.1			
Otner	docume	ent(s) or	information included:
11.	[X]	An In 17(2)	ternational Search Report (PCT/ISA/210) or Declaration under PCT Article (a):
	a.	[X]	is transmitted herewith.
	b.	[]	has been transmitted by the International Bureau.
		г з	Date of mailing (from form PCT/IB/308):
	c.	[]	is not required, as the application was searched by the United States
	d.	[]	International Searching Authority. will be transmitted promptly upon request.
	e.	[]	has been submitted by applicant on
	О.	L J	has been submitted by applicant on Date
12.	[X]	An In	formation Disclosure Statement under 37 C.F.R. 1.97 and 1.98:
	a.	[X]	is transmitted herewith.
			Also transmitted herewith is/are:
		[X]	Form PTO-1449 (PTO/SB/08A and 08B).
		[X]	Copies of citations listed.
	b.	[]	will be transmitted within THREE MONTHS of the date of submission of requirements under 35 U.S.C. 371(c).
	c.	[]	was previously submitted by applicant on
			Date
13.	[]	An as	signment document is transmitted herewith for recording.
	A sepa NEW	arate [] PATEN	"COVER SHEET FOR ASSIGNMENT (DOCUMENT) ACCOMPANYING T APPLICATION" or [] FORM PTO 1595 is also attached.

14.	[X] a. b. c. d.	Additional documents: [X] Copy of request (PCT/RO/101) [X] International Publication No. WO99/15559 i. [] Specification, claims and drawing ii. [X] Front page only [X] Preliminary amendment (37 C.F.R. § 1.121) [X] Other
		Form PCT/IB/306; Form PCT/IB/308; Form PCT/IB/332
15.	[X] a. b.	The above checked items are being transmitted [X] before 30 months from any claimed priority date. [] after 30 months.
16.	[]	Certain requirements under 35 U.S.C. 371 were previously submitted by the applicant on, namely:
WARNI	NG:	AUTHORIZATION TO CHARGE ADDITIONAL FEES Accurately count claims, especially multiple dependent claims, to avoid unexpected high charges if extra claims are authorized.
NOTE:	reply, re incorpor required an exten paragra construc	en request may be submitted in an application that is an authorization to treat any concurrent or future quiring a petition for an extension of time under this paragraph for its timely submission, as atting a petition for extension of time for the appropriate length of time. An authorization to charge all fees, fees under \S 1.17, or all required extension of time fees will be treated as a constructive petition for sion of time in any concurrent or future reply requiring a petition for an extension of time under this of for its timely submission. Submission of the fee set forth in \S 1.17(a) will also be treated as a tive petition for an extension of time in any concurrent reply requiring a petition for an extension of time is paragraph for its timely submission." 37 C.F.R. \S 1.136(a)(3).
NOTE:	nor will	ts of twenty-five dollars or less will not be returned unless specifically requested within a reasonable time, the payer be notified of such amounts; amounts over twenty-five dollars may be returned by check or, if d, by credit to a deposit account." 37 C.F.R. § 1.26(a).
	[X]	The Commissioner is hereby authorized to charge the following additional fees that may be required by this paper and during the entire pendency of this application to Account No. 12-0425.
		[X] 37 C.F.R. 1.492(a)(1), (2), (3), and (4) (filing fees)
WARNII	VG:	Because failure to pay the national fee within 30 months without extension (37 C.F.R. § $1.495(b)(2)$) results in abandonment of the application, it would be best to always check the above box.
		[] 37 C.F.R. 1.492(b), (c) and (d) (presentation of extra claims)

NOTE: Because additional fees for excess or multiple dependent claims not paid on filing or on later presentation must

09/508658 428 Rect PCT/PTO 14 MAR 2000

only be paid or these claims cancelled by amendment prior to the expiration of the time period set for response by the PTO in any notice of fee deficiency (37 C.F.R. \S 1.492(d)), it might be best not to authorize the PTO to charge additional claim fees, except possible when dealing with amendments after final action.

[X] 37 C.F.R. 1.17 (application processing fees)

[X] 37 C.F.R. 1.17(a)(1)-(5)(extension fees pursuant to § 1.136(a).

[X] 37 C.F.R. 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. 1.311(b))

NOTE: Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notice of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notice of allowance. 37 C.F.R § 1.311(b).

NOTE: 37 C.F.R. 1.28(b) requires "Notification of any change in loss of entitlement to small entity status must be filed in the application... prior to paying, or at the time of paying... issue fee." From the wording of 37 C.F.R. § 1.28(b): (a) notification of change of status must be made even if the fee is paid as "other than a small entity" and (b) no notification is required if the change is to another small entity.

[X] 37 C.F.R. § 1.492(e) and (f) (surcharge fees for filing the declaration and/or filing an English translation of an International Application later than 30 months after the priority date).

SIGNATURE OF PRACTITIONER

Reg. No.: 25,858 William R. Evans

(type or print name of practitioner) c/o Ladas & Parry

Tel. No.: (212) 708-1930

26 West 61st Street
P.O. Address

Customer No.: New York, NY 10023

03 Recd PCT/PTO 14 MAR 2000

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PCT/FI98/00749

23 SEPT. 1998

23 SEPT. 1997

INT'L APPLICATION NO.

INT'L FILING DATE

PRIORITY DATE CLAIMED

NOVEL GENE DEFECTIVE IN APECED AND ITS USE

TITLE OF INVENTION

Kai KROHN; Maarit HEINO; Part PETERSON; Hamish SCOTT; Stylianos ANTONARAKIS; Maria LALIOTI; Nobuyoshi SHIMIZU; Jan KUDOH APPLICANT(S)

Attorney Docket: U 012653-9

Commissioner of Patents and Trademarks Washington, D.C. 20231

PRELIMINARY AMENDMENT

Please amend the above application as follows.

In the Claims

Claim 3, line 1, delete " or 2"

Claim 7, line 1, delete "or 6"

Claim 8, line 1, delete "any of claims 5 to 7" and substitute therefor -- claim 5--

CERTIFICATION UNDER 37 C.F.R. 1.10*

(Express Mail label number is mandatory.) (Express Mail certification is optional.)

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on this date <u>MARCH 14, 2000</u> in an envelope as "Express Mail Post Office to Addressee," Mailing Label Number <u>EL386267956US</u>, addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

JENNIFER RASHKIN

(type or print name of person mailing paper)

gnature of person mailing paper

WARNING:

Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

Claim 11, line 1, delete "or 10"

Claim 13, line 1, delete "any one of claims 9 to 12" and substitute therefore --claim 9--

Claim 14, line 1, delete "any one of claims 9 to 14" and substitute therefor --claim 9--

2 3 1900

Claim 15, line 1, delete "any one of claims 9 to 14" and substitute therefor --claim 9--

Claim 18, line 1, delete "or 17"

Claim 19, lines 1-2, delete "any one of claims 1 to 4" and substitute therefor --claim 1--

Claim 20, line 1, delete "any one of claims 5 to 7" and substitute therefor --claim 5--

Claim 21, lines 1-2, delete "any one of claims 1 to 4" and substitute therefor --claim 1--

Claim 22, lines 1-2, delete "any one of claims 1 to 4" and substitute therefor --claim 1--

23. (amended) Reagents reacting with the DNA sequence characterized by comprising the sequence id. no. 1 or a functional fragment or variant thereof encoding a protein having the same functional activity, or an functionally equivalent isolated DNA sequence hybridizable thereto or the protein of claim 5 or with reagents therewith.

Respectfully submitted,

William R. Evans c/o Ladas & Parry 26 West 61st Street New York, NY 10023 Reg. No. 25,858 (212) 708-1930

VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) & 1.27(c))—SMALL BUSINESS CONCERN Docket Number (Optional)
Applicant or Patentee: Finnish Immunotechnology 11d. Serial or Patent No.: Filed or Issued:
Title: Novel gene defective in apeced and its use
I hereby declare that I am
the owner of the small business concern identified below: an official of the small business concern empowered to act on behalf of the concern identified below:
NAME OF SMALL BUSINESS CONCERN Finnish Immunotechnology Ltd. ADDRESS OF SMALL BUSINESS CONCERN Lenkkellijänkatu 8, FIN-33530 Tampere, Finland
I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a faird party or parties controls or has the power to control both.
I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in:
the specification filed herewith with title as listed above. the application identified above. the parent identified above.
If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights in the invention must file separate verified statements aventing to their status as small entities, and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).
Each person, consern or organization having any rights in the invention is listed below;
no such person, concern or organization exists. each such person, concern or organization is listed below.
Separate verified statements are required from each named person, concern or organization having rights to the invention avening to their status as small entities. (37 CFR 1-27)
I acknowledge the duty to file, in this application or pount, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the estilect of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))
Thereby declare that all statements made herein of my own knowledge are true and that all statements made on information and balled are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.
NAME OF PERSON SIGNING Pekka Sillanaukee
TITLE OF PERSON IF OTHER THAN OWNER chief executive officer
ADDRESS OF PERSON SIGNING Lenkkeilijänkatu 8, 33520 TAMPERE FINLAND
SIGNATURE DATE March 7th, 2000

09/5 08658 12 Rec'd PGT/PTO 1 4 MAR 2000 PCT/F198/00749

1

NOVEL GENE DEFECTIVE IN APECED AND ITS USE

Field of the invention

The present invention relates to a novel gene, a novel protein encoded by said gene, a mutated form of the gene and to diagnostic and therapeutic uses of the gene or a mutated form thereof. More specifically, the present invention relates to a novel gene defective in autoimmune polyendocrinopathy syndrome type I (APS I), also called autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) (MIM No. 240,300).

10 Background

Autoimmune polyglandular syndrome type I (APS I), also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a rare recessively inherited disease (MIM No. 240,300) that is more prevalent among certain isolated populations, such as Finnish, Sardinian and Iranian Jewish populations. The incidence of the disease among the Finns and the Iranian Jews is estimated to be 1:25000 and 1:9000, respectively, whereas only few cases in other parts of the world are found each year.

APECED is one of the two major autoimmune polyendocrinopathy syndromes. The causing factor of APECED has not yet been identified. The 20 syndrome is characterized by lack of tolerance to numerous self-antigens and can therefore be considered as a prototype of organ-specific autoimmune diseases. In APECED, the patient develops chronic mucocutaneous candidiasis soon after birth, and later several organ-specific autoimmune diseases, mainly hypoparathyreoidism, Addison's disease, chronic atrophic gastritis with 25 or without pernicious anemia, and in puberty gonadal dysfunction occur [Ahonen P, Clin. Genet. 27 (1985) 535-542]. An accepted criterion for diagnosis of APECED is the presence of at least two of the three main symptoms, Addison's disease, hypoparathyroidism and candidiasis, in patients [Neufeld, M. et al., Medicine 60 (1981) 355-362]. Immunologically, the major 30 findings are the presence of high-titer serum autoantibodies against the effected organs, antibodies against Candida albicans, and low or lacking T-cell responses toward candidal antigens [Blizzard, R. M. and Kyle M., J. Clin. Invest. 42 (1963) 1653-1660; Arulanantham, K. et al., New Eng. J. Med. 300 (1979) 164-168; Krohn, K. et al., Lancet 339 (1992) 770-773; Uibo R. et al., J. 35 Clin. Endocrinol. Metab. 78 (1994) 323-328]. The disease usually occurs in

35

childhood, but new tissue specific symptoms may appear throughout life [Ahonen, P. et al., New Engl. J. Med. 322 (1990) 1829-1836]. APECED is not associated with a particular HLA haplotype, and both males and females are equally affected consistant with the autosomal recessive mode of inheritance.

The locus for the APECED gene has been mapped to chromosome 21g22.3 between gene markers D21S49 and D21S171 based on linkage analysis of Finnish families [Aaltonen, J. et al., Nature Genet. 8 (1994) 83-87]. Recently, Börses et al. reported a maximum LOD score of 10,23 with marker D21S1912 just proximal to the gene PFKL, and thus by linkage disequilibrium 10 studies the critical region for APECED can be considered to be less than 500 kb between markers D21S1912 and D21S171. Locus heterogeneity was not revealed by linkage analysis of non-Finnish families [Björses, P. et al., Am. J. Hum. Genet. <u>59</u> (1996) 879-886].

For the APECED gene, the name "autoimmune regulator" or "AIRE" 15 has been adopted by the scientific community after the priority date of the present application. Similarly the protein encoded by the AIRE gene is now called the "AIRE protein".

Physical maps of human chromosome 21g22.3 have been developed using YACs, and bacterial based large insert cloning vectors 20 [Chumakov et al., Nature 359 (1992) 380; Stone et al., Genome Res. 6 (1996) 218], and many laboratories have contributed to the construction of a transcription map of the whole chromosome and 21q22.3 in particular [Chen et al., Genome Res. 6 (1996) 747-760; Yaspo et al., Hum. Mol. Genet. 4 (1995) 1291-1304]. Numerous trapped exons from chromosome 21 specific cosmids and also physical contigs from the APECED critical region have been identified and partially characterized. In addition, a number of ESTs from the international human genome project have been mapped to the APECED critical region.

Recently, as part of the international efforts of generating the entire 30 sequence of human chromosome 21 and international agreements on the immediate availability of this type of sequence data, the partial sequence of the APECED gene critical region was made available in GenBank by the Stanford Human Genome Center which is currently carrying out the sequencing of 1.0 Mb around the critical region of the APECED gene.

However, the precise location and the sequence of the APECED gene and the nature of the gene product have not so far been clarified. Thus

at present the diagnosis of APECED is based mainly on developed clinical symptoms and typical clinical findings, e.g. the presence of autoantibodies against adrenal cortex or steroidogenic enzymes P450c17 and/or P450scc. The linkage analysis is seldom used. Further, means for natal or presymptomatic diagnosis of the disease are not easily available, since the linkage analysis provides only an indirect data through known gene markers and requires samples from several family members in several generations. Additionally, the linkage analysis is tedious and can be performed only in specialized laboratories by highly-skilled personnel.

Also the mapping of the carriers of the disease gene is presently based on the linkage analysis and thus not readily available.

Summary of the invention

We have now identified a novel gene encoding a novel zinc finger protein, designated as autoimmune regulator 1 or AIR-1, which is mutated in APECED. The novel gene and protein allow further development of the diagnosis and therapy of diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED.

The object of the invention is to provide means which are useful in a diagnostic method and a gene therapeutic method in the diagnosis and treat-20 ment of diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED.

Another object of the invention is to provide a novel method for the diagnosis of diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED, including the pre- and postnatal diagnosis and the mapping of the carriers, the method being easy and reliable to perform.

The present invention relates to an isolated DNA sequence comprising the sequence id. no. 1 or a functional fragment or variant thereof, or a functionally equivalent isolated DNA sequence hybridizable thereto, the DNA sequence being associated with diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED. Preferably said isolated DNA sequence includes a gene defect responsible for APECED.

The present invention also relates to a protein comprising the amino acid sequence id. no. 2 or a functionally equivalent fragment or variant thereof, the protein being associated with diseases related to immune maturation and

regulation of immune response towards self and nonself, such as APECED. Said protein has distinct structural motifs, including the PHD finger motif (PHD), the LXXLL motif (L), proline-rich region (PRR), and cystein-rich region (CRR).

The present invention further relates to a method for the diagnosis of diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED, comprising detecting in a biological specimen the presence of a DNA sequence comprising the sequence id. no. 1 or a functional fragment or variant thereof, or a functionally 10 equivalent DNA-sequence hybridizable thereto, the DNA sequence being associated with diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED.

The present invention further relates to the use of the aboveidentified DNA-sequences in the diagnosis of diseases related to immune 15 maturation and regulation of immune response towards self and nonself, such as APECED.

The present invention further relates to a method for the diagnosis of diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED, comprising detecting in a 20 biological specimen the presence or the absence of a protein comprising the sequence id. no. 2 or a functionally equivalent fragment thereof, the protein being associated with diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED.

The present invention further relates to the use of the above-25 identified protein or a functionally equivalent fragment thereof in the diagnosis of diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED.

The present invention further relates to the use of the aboveidentified DNA sequences in gene therapy or for the preparation of a 30 pharmaceutical preparation useful in a gene therapy method of diseases related to immune maturation and regulation of immune response towards self and nonself, such as APECED.

Brief description of the drawings

Figure 1 shows a physical map of the APECED gene locus in the 35 chromosome 21g22.3. Cosmids D1G8, D40G11, D9G11, D28B11, and D4G11, overlapping clones used for the genomic sequencing [Kudoh, J. et al.,

DNA Res. 4 (1997) 45 -52] are indicated by horizontal lines. The APECED gene located just proximal to the 5' end of the neighboring gene PFKL is indicated by a solid arrow. N indicates Notl sites. DNA marker D21S1912 is shown as open box.

Figure 2 shows the structures of the APECED gene and AIR proteins. (A) Cloning strategy of APECED cDNAs and the order of the exons in the APECED gene. DNA fragments amplified by PCR and 3'- and 5'-RACE are indicated by the lines. Exon 1' is the 5'-noncoding exon of the AIR-2 and AIR-3. An additional alternative splicing of AIR-3 in exon 10, resulting in an 10 amino acid change in its downstream, is indicated by vertical lines. Each exon, except exon 1', is bordered by the common splice site consensus sequence, ag;qt. Mutations in the exon 2 and exon 6 are indicated by the arrows. (B) Schematic presentation of the three AIR proteins showing distinct structural motifs, including the PHD finger motif (PHD), the LXXLL motif (L), 15 proline-rich region (PRR), and cystein-rich region (CRR).

Figure 3 shows electropherograms showing the sequence surrounding the mutations in the APECED gene. (A) Mutation analysis of a Swiss APECED family. The parents are heterozygous for the allele (normal "C" and abnormal "T"). The affected boy and girl show the "C" to "T" transition 20 resulting in the "Arg" to "Stop" nonsense mutation at amino acid position 257. (B) Mutation analysis of two Finnish APECED patients. The patient MP is homozygous for the mutant allele (left), NP is heterozygous for the allele (right). (C) The patient NP shows the "A" to "G" transversion resulting in the "Lys" to "Glu" missense mutation at amino acid position 42. FLEB is a normal 25 control.

Figure 4 shows the result of a restriction enzyme Tagl digestion assay demonstrating the R257stop mutation. Four APECED patients [HP1 (lane 1), HP2 (lane 2), NP (lane 6), and MP (lane 8)], the mothers of two families [HM (lane 5) and NM (lane 7)], two healthy siblings [HN1 (lane 3) and HN2 30 (lane 4)] of family H and normal controls [C1, C2 and C3 (lanes 9-11)] are shown. The APECED patients HP1, HP2 and MP are homozygotes for the R257stop mutation. The APECED patient NP is heterozygous for the R257stop mutation but is carrying a mutation at a different position in another allele of the APECED gene (shown above in Fig. 3C). Both mothers (HM and 35 NM) and two healthy siblings (HN1 and HN2) are heterozygous for the R257stop mutation and therefore carriers of APECED but are not having the

30

disease. Two controls (C1 and C2) are both homozygous for normal alleles. Normal alleles produce a lower 225 bp fragment, the mutated fragment is upper band at 285 bp.

Figure 5 shows an amino acid sequence alignment for the PHD 5 finger motif of AIR-1, Mi-2, and TIF1. The consensus amino acid residues conserved in the PHD finger motif is indicated by the bold letters underneath. The residues that are identical with AIR-1 (aa 299-340) are shown by the dots. GenBank accession nos. of Mi-2 and TIF1 are X86691 and AF009353, respectively.

Figure 6 is a Western blot showing the expression of AIR-1 in fetal liver. A sample of fetal liver was run on PAGE, transferred to a nitrocellulose filter and probed with sera as follows: Lane 1, control mouse serum, lane 2, control mouse serum absorbed with peptide AIR-1/2 (sequence id. no. 25), lanes 3 and 4, serum from a mouse immunized with peptide AIR-1/2 for four 15 and six weeks, respectively and absorbed with peptide AIR-1/2, lanes 5 and 6, unabsorbed serum from a mouse immunized with peptide AIR-1/2 for four and six weeks, respectively. The strong band seen in lanes 5 and 6 represent the AIR-1 protein with a molecular weight of approx. 58 kD, the lower band is an approx. 20 kD breakdown product of the AIR protein. The bands seen in all 20 lanes are non-specific.

Figure 7 shows the expression of the APECED mRNA (7A) or the AIR protein (7B, 7C and 7D) demonstrated by in situ hybridization (7A) or by immunohistochemistry (7B, 7C and 7D). Figure 7A shows APECED mRNA positive cells scattered in the medullary region of human thymus. Figure 7B 25 shows similar cells with the same localization now stained for the AIR protein. Figure 7C is a higher magnification of 7B, showing the localization of the AIR protein in the nuclei. Note the speckled localiation pattern in the nuclei. Figure 7D shows the cytoplasmic localization of the AIR protein in a few cells in lymph node medulla.

Figure 8 shows the phenotypic characterization of the APECED reactive cells in thymus by double-immunofluorescence. The AIR protein is seen as red colour in the nuclei, forming typical speckled pattern with nuclear dots. In Figure 8A, the co-staining is with an antibody recognizing low molecular weight markers (AE1). The APECED positive cells fall into two 35 types, one is expressing cytokeratin and is thus epithelial cell, the other one is non-epithelial and do not co-express cytokeratins. In Figure 8B an APECED positive cell co-epresses a marker (CD83) typical for cells belonging to monocyte-macrophage-dendritic cell lineage.

Figure 9 shows the expression of the AIR protein, demonstrated by immunofluorescence, in mature, activated dendritic cells from peripheral blood.

The expression of the AIR protein shows as distinct dots in the nuclei of dendritic cells.

Detailed description of the invention

The present invention is based on studies aiming for the identification and characterization of the gene defect in APECED. In the sequence studies, a cosmid/BAC (bacterial artificial chromosome) contig of 520 kb covering four gene markers D21S1460-D21S1912-PFKL-D21S154 [Kudoh, J. et al., DNA Res. 4 (1997) 45-52] was constructed, and genomic sequencing in this region was performed [Kawasaki, K. et al., Genome Res. 7 (1997) 250-261]. From this genomic sequence information the distance between D21S1912 and PFKL was determined to be approximately 140 kb (Fig. 1).

Using a computer program, such as GRAIL and GENSCAN [Uberbacher, E. C. and Mural, R. J., Proc. Natl. Acad. Sci. USA <u>88</u> (1991) 11261-11265; Burge, C. and Karlin, S., J. Mol. Biol. <u>268</u> (1997) 78-94], gene screening in the partial sequencing data within this region was performed. GENSCAN predicted several genes between D21S1912 and PFKL. One of these genes located just proximal to the PFKL gene contained the previously trapped exon HC21EXc33 [Kudoh, J. et al., DNA Res. <u>4</u> (1997) 45-52] or MDC04M06 [Chen, H. et al., Genome Res. <u>6</u> (1996) 747-760]. A set of primers for polymerase chain reaction (PCR) was then designed from the predicted exons. The PCR screening of various cDNA libraries using these primers allowed the isolation of a cDNA clone containing the exon HC21EXc33 (exon 13) from the thymus cDNA library (Fig. 2A).

A 3'-rapid amplification of cDNA ends (3'-RACE) and 5'-RACE using Marathon TM cDNA Amplification Kit (Clontech Laboratories Inc, California, USA) according to manufacturer's protocol from the thymus cDNA library was performed using a primer c33F (sequence id. no. 7) and a primer 1R (sequence id. no. 8), respectively.

Sequencing analysis revealed a unique sequence of 2027 bp in overlapping PCR products that contains a 1635-bp open reading frame (ORF) from methionine at nt 128 to a TAG stop codon at nt 1763 encoding a predic-

ted novel protein designated AIR-1, for <u>autoimmune regulator 1</u>. AIR-1 encodes a protein of 545 amino acids with a predicted isoelectric point of 7.32 and a calculated molecular mass of 57,723 (Fig. 2B).

A 5'-RACE from the thymus cDNA using a primer 4R (sequence id. no. 9) resulted in an alternatively spliced product. Furthermore, two types of the cDNA clones were amplified with a primer pair 3F/c33R (sequence id. no. 10/sequence id. no. 11) and these clones encode for AIR-2 and AIR-3 proteins, sequence id. no. 4 and sequence id. no. 6, respectively (Fig. 2A) (sequence id. no. 3 and sequence id. no. 5). The AIR-2 and AIR-3 proteins consist of 348 and 254 amino acids, respectively (Fig. 2B). These results suggest that the APECED gene is transcribed as at least three types of mRNA by alternative splicing and/or use of an alternative 5' exon within the gene. RT-PCR analysis [Griffin, H. G. and Griffin, A. M., PCR Technology. Current Innovations, CRC Press, 1994] revealed that the AIR-1 transcript is also expressed in fetal liver (data not shown).

The APECED gene is approximately 13-kb in length and contains 15 exons, including the exon 1' specific to AIR-2 and AIR-3. It is transcribed in the direction of centromere to telomere (Figs 1, 2A). Based on this information, PCR primers were designed to amplify each exon from the genomic DNA and a mutation analysis of Swiss and Finnish APECED families was performed. Sequence comparison identified two mutations in the APECED gene of the patients (Fig. 3). The first mutation changes an Arg codon (CGA) to a stop codon (TGA) at amino acid position 257 in exon 6. This mutation was designated as R257stop mutation. The second mutation is a missense mutation that derived from the maternal chromosome in one Finnish patient (NP): a Lys codon (AAG) changes to a Glu codon (GAG) at amino acid position 42 in exon 2. This mutation is designated as K42E mutation (Figs 2A, 3C).

The R257stop mutation destroys a *Taq*I restriction enzyme site and the K42E mutation introduces a novel *Taq*I site. Thus these two mutations can be easily demonstrated in one or both alleles by *Taq*I digestion or by digestion using another enzyme cleaving at the recognition site 5'-TCGA-3'(Fig. 4).

The AIR-1 protein has strong homology in certain domains to the major autoantigens (Mi-2) associated with the autoimmune disease dermatomyositis [Seeig, H. P. et al., Arthritis Rheum. 38 (1995) 1389-1399; 35 Ge, Q. et al., J. Clin. Invest. 96 (1995) 1730-1737], Sp140, a protein from the nuclear body, an organelle involved in the pathogenesis of certain types of

leukemia, and which is also the target of antibodies in the serum of patients with the autoimmune disease primary bilary cirrhosis [Bloch, D. B. et al., J. Biol. Chem. 271 (1996) 29198-29204]. in addition, the homologies extend to other nuclear proteins such as TIF1 [Le Douarin, B. et al., EMBO J. 14 (1995) 2020-2033], LYSP100 [Dent, A. L. et al., Blood 88 (1996) 1423-1426], and putative yeast and C. elegans proteins. The AIR-1 protein homologies are principally in two PHD finger motifs (amino acid 299 to 340 and 434 to 475) (Fig. 5). AIR-1 also contains a proline-rich region (amino acid 350 to 430) (Fig. 2B). The PHD finger is a cysteine-rich structure that is distinguished from the 10 RING finger (C3HC4) and LIM domain (C2HC5) because it contains a consensus of C4HC3. [Aasland, R. et al., Trends Biochem. Sci. 20 (1995) 56-59]. The PHD finger motif is found in a number of chromatin-associated proteins such as HRX that is involved in the t(11:17) translocation in acute leukemia [Chaplin, T. et al., Blood 86 (1995) 2073-2076]. The proline-rich region is 15 assumed to be involved in protein-protein interaction or DNA binding. The presence of the PHD finger and proline-rich regions indicates a function for AIRs as transcription regulatory proteins. However, the AIR proteins have no apparent nuclear translocation signal, and thus other proteins containing such signal may interact with AIR to translocate it to the nucleus. In fact, the AIR 20 proteins also have the LXXLL motif that is a signature sequence to bind to nuclear receptors [Heery, D. M. et al., Nature 387 (1997) 733-736] (Fig. 2B).

The clinical picture of APECED and the observed immunological abnormality with strong autoimmune response towards several target organs and antigens suggest that the product of the APECED gene has a central role in immune (ontogeny) maturation and regulation of immune response towards self and nonself.

According to the diagnostic method of the invention, the presence of the defective APECED gene can be detected from a biological sample by any known detection method suitable for detecting mutations. Such methods include the method described by Saiki *et al.* [Proc. Natl. Acad. Sci USA <u>86</u> (1989) 6230-6234) utilizing hybridization to an allele specific oligonucleotide probe, or modifications thereof; the method described by Newton, C. R. *et al.* [Nucl. Acids Res. <u>17</u> (1989) 2503-2516] using the DNA sequences or DNA-fragments of the invention as probes; the solid phase minisequencing method described by Syvänen *et al.* [Genomics <u>8</u> (1990) 684-692] in which use is made of a biotinylated probe; or the oligonucleotide ligation method described

by Landegren, U. *et al.* [Science <u>241</u> (1988) 1077-1080]. Methods include the denaturing gradient gel electrophoresis (DGGE) [Fischer, S.G. and Lerman, L.S., PNAS <u>80</u> (1983) 1579-1583] or a modification of this method, constant denaturant gel electrophoresis (CDGE) [Hoving *et al.*, Genes Chromosomes Cancer <u>5</u> (1992) 97-103]. The mutation separation principle of DGGE and CDGE is based on the melting behavior of the DNA double helix of a given fragment.

Since the mutations of the APECED gene involve a site sensitive to *Taq*I digestion, the mutation are preferably detected in one or both alleles by 10 *Taq*I digestion or by digestion using another enzyme cleaving at recognition site 5'-TCGA-3' The chemical mismatch cleavage for mutation analysis can be used [Grompe, M. *et al.*, Proc. Natl. Acad. Sci. USA <u>86</u>(15)(1989) 5888-5892].

In the diagnostic method of the invention the biological sample can be any tissue or body fluid containing cells, such as blood, e.g. umbilical cord blood, separated blood cells, such as lymphocytes, B-cells, T-cells etc., biopsy material, such as fetal liver or thymus biopsy, sperm, saliva, etc. The biological sample can be, where necessary, pretreated in a suitable manner known to those skilled in the art.

When the DNA sequence of the present invention is used 20 therapeutically any techniques presently available for gene therapy can be employed. Accordingly, in the technique known as ex vivo therapy patient cells (e.g. umbilical cord blood from the fetus) with the defective gene are taken from the patient, DNA sequences encoding the normal (healthy) gene product incorporated in a carrier vector are transducted or transfected to the cells and 25 the cells are returned to the patient. If the techniques known as in situ therapy is used, the DNA sequences encoding the normal gene product are first inserted to a suitable carrier vector, and the carrier is then introduced to the affected tissue, such as peripheral blood, liver or bone marrow. The carrier vector used can be a retrovirus vector, an adeno virus vector, an adeno associated virus (AAV) vector or an eucaryotic vector. The therapy can be performed intra utero or during adult life. Depending on the cells to be treated these techniques lead either to a transient cure, where cells from affected organ are treated, or to a permanent cure, in case of the treatment of stem cells.

The present invention provides means for an easy and more rapid diagnosis of the diseases related to immune maturation and regulation of

immune response towards self and nonself, such as APECED, and, specifically, enables prenatal diagnosis and carrier diagnosis. Furthermore, it provides a background for therapy.

The invention is now elucidated by the following non-limiting 5 examples.

Example 1

Localization of the APECED gene

Genomic sequencing of cosmid DNAs was performed by the shotgun method described by Kawasaki, K. et al., Genome Res. 7 (1997) 250-10 261. Cosmids D1G8, D40G11, D9G11, D28B11, and D4G11 and gene marker D21S1912 are described by Kudoh, J. et al., DNA Res. 4 (1997) 45-52].

cDNA cloning

The phage DNAs prepared from human thymus cDNA library (Clontech, HL1127a) were used as a PCR template. 20 ng of phage DNA which represents approximately 4x10⁸ phages was added to a 10 ml of reaction mixture containing 1x buffer [16mM (NH₄)₂SO₄, 50mM Tris-HCl, pH 9.2, 1.75 mM MgCl₂, 0.001% (w/v) gelatin), 0.2 mM each of dNTPs, 1M Betaine (Sigma), 0.35 U of Tap and Pwo DNA polymerase (EXpand Long Template PCR System, Boehringer Mannheim), and 0.5 mM of each of the primers, 2F and c33R, 2F and 4R, and 2F' and 2R', respectively.

The cDNA fragment was amplified by PCR using the following conditions: 94°C for 3 min., 35 cycles of 94°C for 30 sec, 60 °C for 30 sec in 2F/c33R and 2F/4R or 65°C for 30 sec in 2F'/2R', and 68°C for 90 sec. 3'- and 5'-RACE were carried out by Marathon cDNA Amplification Kit (Human Thymus; Clontech). PCR reaction was performed in a 10 µl volume containing 1x buffer (50 mM KCl, 10 mM Tris-HCl, pH 8.3, 1.5 mM MgCl₂, 0.001% (w/v) gelatin), 0.2 mM each of dNTPs, 0.25 U of AmpliTaq Gold polymerase (Perkin-Elmer), and 0.5 mM of each of the exon-specific primers. 3'-RACE product was amplified by PCR with the following conditions: 95°C for 9 min., 35 cycles of 94°C for 30 sec, 60°C for 30 sec, and 72°C for 30 sec.

The cDNA fragments were sequenced by the dye deoxy terminator cycle sequencing method (according to ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit protocol P/N 402078, Perkin Elmer Corporation, California) using specific primers, 2F and c33R, and AmpliTaq/FS

DNA polymerase (Perkin-Elmer), and then analyzed by using an automatic DNA sequencer (Applied Biosystems 377). Primer sequences used were

1R: 5'-GTTCCCGAGTGGAAGGCGCTGC-3' (sequence id. no. 8)

2F: 5'-GGATTCAGACCATGTCAGCTTCA-3' (sequence id. no. 12)

3F: 5'-GAGTTCAGGTACCCAGAGATGCTG-3' (sequence id. no.

10)

5

10

30

c33R: 5'-CTCGCTCAGAAGGGACTCCA-3' (sequence id. no. 11)

4R: 5'-AGGGGACAGGCCAGGT-3' (sequence id. no. 9)

2F': 5'-GTGCTGTTCAAGGACTACAAC-3' (sequence id. no. 13)

2R': 5'-TGGATGAGGATCCCCTCCACG-3' (sequence id. no. 14)

AP1: 5'-CCATCCTAATACGACTCACTATAGGGC-3' (sequence id.

no. 15) and

c33F: 5'-GATGACACTGCCAGTCACGA-3' (sequence id. no. 7).

Example 2

15 Mutation analysis of the APECED gene

For the mutation analysis the DNA samples were purified from periferal blood mononuclear cells from patients with APECED and from suspected carriers of APECED and from normal healthy controls (according to Sambrook *et al.* 1989, Molecular Cloning. A Laboratory Manual. CSH Press) and subjected to PCR using primers specific for all identified exons.

For sequencing the mutated exons, PCR fragments, 6F/6R in exon 6 and 49300F/49622R in exon 2, were amplified by PCR with the following conditions: 95°C for 9 min., 35 cycles of 94°C for 30 sec, 60°C for 30 sec and 72°C for 30 sec, and 94°C for 3 min., 35 cycles of 94°C for 30 sec, 60°C for 30 sec, and 68°C for 30 sec, respectively. The PCR products were sequenced using specific primers

6F: 5'-TGCAGGCTGTGGGAACTCCA-3' (sequence id. no. 16)

6R: 5'-AGAAAAAGAGCTGTACCCTGTG-3' (sequence id. no. 17)

3R: 5'-TGCAAGGAAGAGGGGCGTCAGC-3' (sequence id. no. 18)

49300F: 5'-TCCACCACAAGCCGAGGAGAT-3' (sequence id. no. 19) and 49622R: 5'-ACGGGCTCCTCAAACACCACT-3' (sequence id. no. 20).

In the mutation analysis by sequencing, two Swiss and three Finnish (HP1, HP2 and MP) patients with APECED were homozygous for R257stop allele, whereas one Finnish patient (NP) was heterozygous for this mutation (Fig. 3A, B). The R257stop mutation of NP was derived from the

paternal chromosome. The second mutation, K42E mutation, was found in one Finnish patient (NP): a Lys codon (AAG) changes to a Glu codon (GAG) at amino acid position 42 in exon 2.(Figs 2A, 3C). This mutation derived from the maternal chromosome.

5 Example 3

Restriction enzyme Taql analysis of two mutations in exons 2 and 6 of APECED gene

Analysis of the mutation sites in exons 2 and 6 in large series of individuals was performed using the restriction enzyme Taql.The Taql digestion for exons 2 and 6 was done as follows. Ten microlitres of amplification product was incubated at 65°C for 1 hour in 20 μl of reaction mixture containing 1x Taql digestion buffer (New England Biolabs, NY, 100 μl/ml of BSA and 10U of Taql enzyme (New England Biolabs, NY). After the digestion fragments were separated in 1.5% agarose gel and visualized by EtBr staining.

For exon 2, the fragment containing the mutation site K42E was amplified with primers GR1/2F and GR1/2R with the following conditions: 95°C for 3 min., 35 cycles of 94°C for 30 sec, 62°C for 30 sec and 72°C for 1 min. The 1x reaction mix used contained 50 mM KCl, 10 mM Tris-HCl, pH 8.3, 1.5 mM MgCl₂, 0.001% (w/v) gelatin), 0.2 mM each of dNTPs, 0.25 U of Dynazyme (Finnzymes, Finland), and 0.5 mM of each of the exon-specific primers. The normal allele produces a 312 bp fragment whereas the mutated allele gives a 133 bp and a 179 bp fragment. Primer sequences for GR1/2F and GR1/2R are 5'-TGGAGATGGGCAGGCCGCAGGGTG (sequence id. no. 21) and 5'-CAGTCCAGCTGGGCTGAGCAGGTG (sequence id. no. 22), respectively.

For exon 6, the fragment containing the R257stop mutation site was amplified with primers GR1/5IF and GR1/5IR with the same conditions described for exon 2 (see above). The normal allele produces a 225 bp fragment whereas the mutated allele gives a 285 bp fragment. Primer sequences for GR1/5IF and GR1/5IR are 5'-GCGGCTCCAAGAAGTGCATCCAGG (sequence id. no. 23) and 5'-CTCCACCCTGCAAGGAAGAGGGGC (sequence id. no. 24), respectively.

The screening of 50 Finnish and 50 Swiss healthy individuals did not reveal R257stop or K42E mutations by *Taq*l digestion. Similarly, PCR ana-

lysis of 20 unaffected Japanese was performed and no mutations were found in any of these positions. These results demonstrate that the APECED gene is responsible for the pathogenesis of APECED.

Mutations were found in the AIR-1 transcript but not in the AIR-2 and AIR-3 transcripts from all the APECED patients tested. Two Swiss and three Finnish (HP1, HP2 and MP) patients who are homozygous for the R257stop mutation completely lack functional AIR-1 protein but still have intact AIR-2 and AIR-3 proteins.

One common mutation seems responsible for the genetic defect in approximately 90% of the Finnish APECED cases and a haplotype analysis with the markers D21S141, D21S1912 and PFKL shows that the R257stop mutation is likely to be this common mutation [Björses, P. et al., Am. J. Hum. Genet. 59 (1996) 879-886].

Example 4

15 Analysis of the AIR protein expression

In this example, synthetic peptides representing amino-acid sequences of the AIR-1 protein, were used to generate a polyvalent mouse antiserum against the AIR-1 protein.

For the peptide synthesis, two peptides were chosen according to the antigenicity prediction by Pepsort program (GCC package, Wisconsin, USA). The peptides AIR-1/2 and AIR-1/6 (TLHLKEKEGCPQAFH, sequence id. no. 25 and GKNKARSSSGPKPLV, sequence id. no. 26, respectively) representing exons 2 and 6, respectively, of the APECED gene were synthesized onto a branched lysine core (Fmoc8-Lys4-Lys2-Lys-betaAla-Wang resin, Calbiochem-Novabiochem, La Jolla, Ca, USA) resulting in an octameric multible antigen peptide (MAP) [Tam, J. P. et al., Proc. Natl. Acad. Sci. USA 85 (1988) 5409-5413; Adermann, K. et al., in Solid Phase Synthesis, Biological and Biomedical Applications, pp. 429-432, Ed. R. Epton, Mayflower Worldwide Ltd., Birmingham, 1994], Syntheses were performed by Fmoc (N-9-fluorenyl)methoxycarbonyl) chemistry on a simultaneous multiple peptide synthesizer (SMPS 350, Zinsser Analytic, Frankfurt, Germany). Purity of MAPs was analyzed by reverse-phase HPLC (System Gold, Beckman Instruments Inc, Fullerton, CA, USA).

To obtain murine polyclonal antibodies, eight-week old Balb/c mice 35 were immunized with an intraperitoneal injection of 25 micrograms of each

peptide in 0,4 ml of a 1:1 mixture of Freund's Complete Adjuvant (Difco Laboratories, Detroit, Ml, USA) and physiological saline (NaCl, 0,15 M). One month later the animals were boosted with an intramuscular injection of 35 micrograms of antigens in Freund's incomplete adjuvant and saline (1:1) (0,2 ml were distributed into four sites). Three weeks later the peptides in a dose of 50 micrograms/mouse were administered intravenously and sera were obtained 7 days later.

For the production of EBV transformed B-cells, peripheral blood leukocytes were obtained from healthy control persons. The B-cells were transformed with EBV (Epstein-Barr virus) using standard protocol, and the cell lines were maintained in RPMI 1640, supplemented with 10% FCS (fetal calf serum). An aliquot of cells were stimulated for 12 hours with 10 mg/ml of phytohemagglutinin (PHA) to obtain mitogen-activated T-cells.

Tissue samples were obtained from stillborn fetuses at six months 15 gestational age. Fetal liver, spleen, thymus and lymphnodes were homogenized, the homogenates were cleared with centrifugations (20 000 rpm for 20 minutes) and the samples were used for western blot analysis.

For analysis of polyclonal sera, Elisa and western blot analysis were performed. Microtitre ELISA plates (Maxisorp, Nunc, Roskilde, Denmark) were coated with the peptides (1 micrograms /well in PBS, pH 7,5) at 4°C overnight and blocked with 2 % of BSA in PBS. The plates were then incubated with titrated mouse immune sera and normal (control) sera at room temperature for 4 h. Finally the bound peptide-specific antibodies were detected by use of anti-mouse HRP-labelled immunoglobulins (Dako A/S, Denmark) essentially as previously described [Ovod, V. A. et al., AIDS 6 (1992) 25-34].

For western blotting, tissue homogenates, EBV transformed B-cells or PHA-activated T-cells were boiled for 10 minutes in 2x sample buffer (for tissue homogenates: 100 microliters of homogenate mixed with 100 microliters of sample buffer; for cells: one million cells/100 ml of buffer) and analyzed in western blotting as described in Ovod, V. A. *et al.*, *supra*.

The antisera so produced reacted with the AIR-1-protein low amount in normal fetal spleen, thymus and lymphonode as well as, in EBV-transformed B-cells and in PHA-activated T-cells. In the ELISA assay towards the immunogenic peptides, all four mice gave a strong reactivity towards the peptide used for the immunization. In the western blotting analysis using either

the tissue homogenates or stimulated T-cells or established B-cells, a strong band of approx. 60 kD molecular weight was seen in fetal liver (Fig. 6), while weaker bands of the same size were seen in the other samples.

Example 5

5 Identification of the expression of APECED in thymus and other lymphoid organs

mRNA in situ hybridization and immunohistochemistry were used to identify APECED-expressing cells in various normal fetal and adult human tissues. Thymus samples were obtained in conjunction of corrective surgery 10 from cardiac patients aged 2-19 years. Other tissue samples were obtained from surgical biopsy or from autopsy material. This was approved by Hospital Ethics Committees at Tampere University Hospital and Helsinki University Central Hospital. The tissue materials were stored frozen or formaldehyde fixed and paraffin embedded until used.

For mRNA in situ hybridization, three cDNA fragments for riboprobes were amplified by RT-PCR from thymus mRNA (Clontech) with primer pairs: 5'-ATG GCG ACG GAC GCG GCG CTA CGC-'3 (seg. id. no. 27) and 5'-CCT GGA TGT ACT TCT TGG AGC CGC-3' (seg. id. no. 28), 5'-GAG CCC GAG GGG CCG TGG AGG GGA-3' (seq. id. no. 29) and 5'-GGC TGC 20 ACC TCC TGG ACT GTT GCC-3' (seq. id. no. 30), and 5'-GAT CCT GCT CAG GAG ACG TGA CCC-3' (seq. id. no. 31) and 5'-CAC CAG GCA AGG AGA GGC TCC CGG-3' (seq. id. no. 32), designed to amplify fragments spanning nucleotides 137 - 812, 738 - 1185 and 1554 - 2009 of the sequence id. no. 1, respectively. The amplified fragments were subcloned into a pCRII-25 TOPO vector (Invitrogen).

For in vitro transcription the plasmids were linearized and sense and antisense probes were synthesized with digoxigenin-UTP as described (Boehringer Mannheim Nonradioactive in situ Hybridization Application Manual). Labeled probes were purified with MicroSpinG-50 columns 30 (Pharmacia Biotech). The pretreatment and hybridization of formaldehyde fixed, paraffin embedded tissue sections were performed as described by H. Breitschopf and G. Sucharek. (Boehringer Mannheim Nonradioactive in situ Hybridization Application Manual, Detection of mRNA on paraffin embedded material of the central nervous system with DIG-labeled RNA probes, pp 136-35 138.)

For the preparation of antibodies to the AIR protein, the APECED cDNA (sequences 137 - 1774 of sequence id. no. 1) containing a full-coding region was amplified from Marathon human thymus cDNA (Clontech) with primers ExF and ExR2. The primer sequences for ExF and ExR2 were 5'-5 CCA CCC CAT GGC GAC GGA CG-3' (sequence id. no. 33) and 5'-GGA ATT CGG AGG GGA AGG GGG CCG CCG GA-3' (sequence id. no. 34). The amplified cDNA was digested with Ncol and EcoRI and cloned (pHPAIRE) into pET32a vector (Novagen). The protein was expressed in E. coli and purified by His-tag as described by manufacturer (QiaExpress Type IV Kit. Cat No. 10 32149, Qiagen, USA).

To obtain murine polyclonal antibodies, Balb/c mice were immunised essentially as described in Example 4 using 100 micrograms of the bacterially expressed AIR protein with booster doses of 25 and 25 micrograms.

Japanese white rabbits were immunised with a synthetic peptide 15 representing amino acids 526-545 (DGILQWAIQSMARPAAPFPS, sequence id. no. 36) of sequence id. no. 2. The specificities of the antisera were checked with ELISA and Western blotting using standard procedures.

For immunocytochemistry, frozen sections of tissue samples were 20 fixed for 20 min in 4% paraformaldehyde. The AIR antibody (rabbit or mouse) in an appropriate dilution was incubated for 30 min at 37°C, with a biotin conjugated anti-mouse or anti-rabbit secondary antidody (Vector, CA, USA). The biotinylated antibody was revealed by incubating with Texas Red-avidin (Vector, CA, USA) for 30 min at 37°C.

With in situ hybridization, a positive signal was seen in a few cells in thymus medulla (Fig. 7A). The APECED in situ -positive cells were infrequent and scattered as single cells in the medulla, but occasionally one or two APECED-expressing cells were seen adjacent to or buried into the Hassal's corpuscles that represent conglomerates of medullary epithelial cells. In the 30 positive cells, APECED mRNA was predominantly localized in the cell nucleus. In human adult lymph node tissues, infrequent cells expressed APECED mRNA in the medulla and occasionally in the paracortical region, too (Fig. 7B) No hybridization signal was seen in the germinal centers.

Immunohistochemistry with mouse and rabbit polyclonal antisera to 35 the AIR protein showed strong reactivity with selected cells in thymus medulla. lymph nodes and fetal liver (Fig. 7C and 7D) The comparison of the reaction

pattern obtained by immunohistochemistry to that obtained by in situ hybridization clearly established that specific, rare cells in thymus medulla and lymph node medulla and paracortex express APECED mRNA and the AIR protein. By either method, neither mRNA nor protein was detected in other 5 adult tissues studied, including the target organs for tissue destruction in APECED (adrenal glands, parathyroid glands, gonads). In human fetal tissues. APECED positive cells were seen, although extremely infrequently, in the stroma of placental chorionic villi and in the sinusoidal area of the liver. In the fetal liver, the APECED positive cells were often localized pairwise like mirror 10 images, suggesting that the cells were undergoing mitosis. Rare APECED expressing cells were also found in fetal thymus but the expression was not observed in other fetal tissues.

At the subcellular level, the AIR protein localized in small nuclear dots in the adult thymus, giving a characteristic speckled pattern (Fig. 7C; and 15 Fig. 8A and 8B), but localized in the cytoplasm of cells in lymph nodes. In the rare positive cells in fetal liver, many of which were mitotic, the AIR protein was localized in the cytoplasm.

Example 6

25

Characterization of the phenotype of the APECED positive cells in 20 thymus

Double staining with two antibodies was used to further characterize the cell type expressing APECED gene. In view of the fact that dendritic cells (DC) and thymus epithelium are both involved in the regulation of immune maturation, expression of markers for these cells were studied.

For double immunofluorencence detection the AIR staining was performed as described in example 5 with rabbit anti-AIR serum. The slides were then incubated with a second primary antibody [AE1 (Neomarkers, CA, USA), AE3 (Neomarkers, CA, USA), CD11c (Immunotech, France), or CD83 (Immunotech, France)] in an appropriate dilution for 30 min at 37°C, and the 30 reaction was revealed by incubating with a FITC conjugated secondary antimouse antibody (Vector, CA, USA) for 30 min at 37°C.

Antibodies reacting with low molecular weight basic (AE1) or high molecular weight acidic (AE3) cytokeratins stained the thymus in a reticular fashion, and the APECED positive cells were seen either buried into this net 35 or in close apposition with the keratin-positive cells. Confocal microscopy

clearly demonstrated that some of the APECED positive cells were cytokeratin positive while some remained negative (Figure 8A). A colocalization was stronger with AE1 than with AE3. The distribution of epithelial (AE1 positive) and non-epithelial APECED expressing cells varied but in most thymus preparates more than half were epithelial.

Less than half of the APECED expressing cells in thymus stained with markers CD11c and CD83 that react with cells of the monocyte-macrophage-dendritic cell lineage. In most cases, the staining reaction was weak but a few cells showed an intensive staining with the given marker (Fig. 8B). CD83 costained 5 to 40 % of the APECED positive cells. Antibody CD11c, reported to be specific for mature dendritic cells, reacted with up to 5 - 10 % of the APECED positive cells. All APECED positive cells were strongly positive for HLA-DR staining, however (data not sown).

These results suggest that in thymus the APECED gene is in fact expressed in two distinct cell populations, one epithelial and the other non-epithelial. The latter cell type is likely the one also expressing the APECED gene in extrathymic lymphoid tissues.

Example 7

20

APECED expression in stimulated dendritic cells in vitro

To show an APECED expression in dendritic cells derived from peripheral blood monocytes that are DC precursors, these cells were cultured at the presence of cytokines using conditions that are known to lead to the expansion and maturation of dendritic cells.

Peripheral blood mononuclear cells were isolated by Ficoll-Hypaque centrifugation, and adherent cells were separated and cultured in the presence of human recombinant GM-CSF (1000 units/ml) and rhIL-4 (1000 units/ml, both from R&D Systems), as described [Schuler, G. and Romani, N., Adv. Exp. Med. Biol. 417 (1997) 7 - 13]. Cells were further cultured for three days with 1/4 V/V of macrophage conditioned media. Cells were harvested at two days intervals and samples were prepared for RT-PCR. For RT-PCR total RNA was purified from DCs by using a commercial kit from Clontech (USA) (Nucleospin RNA Kit) according to manufacturer's instructions. An aliquot of RNA was transferred into cDNA with a commercial kit from Pharmacia (Sweden) (First-strand Synthesis Kit) and PCR for this DNA sample was performed. For PCR the fragment was amplified with primers 5'- GAT CCT

GCT CAG GAG ACG TGA CCC-3' (seq. id. no. 31; 1554 -1577 of seq. id. no. 1) and 5'-GGA CTG AGG AAG GAG GTG TCC TTC -3' (seq. id. no. 35; 1818-1841 of seq. id. no. 1) with the following conditions: 35 cycles of 95°C for 1 min., 62°C for 30 sec and 72°C for 1 min. The 1x reaction mix contained 50mM KCl, 10mM Tris-HCl, pH8.3, 1.5mM MgCl₂, 0.001% (w/v) gelatin, 0.2mM each of dNTPs, 0.25 U of Dynazyme (Finnzymes, Finland). A fragment of 287bp was detected by 1.5% agarose electrophoresis.

Cytospin preparations were further made for immunohistochemistry. During this 7 to 10 days culture period approximately half of the 10 cells developed the characteristic veiled morphology of DC and their phenotypic cell markers (CD11cand CD83) corresponded to mature DCs (Figure 9). The APECED expression was studied by RT-PCR and immunocytochemistry at two to three days intervals. In the starting material, i.e. the adherent cell pool from peripheral blood, no APECED expression was found. After seven days of culture in the presence of GM-CSF and IL-4, RT-PCR showed APECED mRNA expression and immunofluorescence showed a few AIR specific nuclear dots. After an additional 3-day-culture with conditioned medium from macrophage cultures a strong speckled pattern of nuclear AIR expression was seen (Figure 9A). The RT-PCR analysis of the mature (10 days) culture confirmed the AIR protein expression.

SEQUENCE LISTING

	(1)	GENERAL	INFORMATION
--	---	---	---	---------	-------------

- (i) APPLICANT:
 - (A) NAME: Kai Krohn et al.
 - (B) STREET: Iltarusko, Salmentaantie 751
 - (C) CITY: 36450 Salmentaka
 - (E) COUNTRY: Finland
 - (F) POSTAL CODE (ZIP): none
- (ii) TITLE OF INVENTION: Novel Gene
- (iii) NUMBER OF SEQUENCES: 26
- (iv) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
- (2) INFORMATION FOR SEQ ID NO: 1:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2036 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 137..1774
 - (D) OTHER INFORMATION:/product= "AIR-1"
 - (ix) FEATURE:
 - (A) NAME/KEY: mat peptide
 - (B) LOCATION:137..1771
 - (D) OTHER INFORMATION:/product= "AIR-1"
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
- AGACCGGGGA GACGGGCGGG CGCACAGCCG GCGCGGAGGC CCCACAGCCC CGCCGGGACC
- CGAGGCCAAG CGAGGGGCTG CCAGTGTCCC GGGACCCACC GCGTCCGCCC CAGCCCCGGG 120
- TCCCCGCGCC CACCCC ATG GCG ACG GAC GCG GCG CTA CGC CGG CTT CTG 169 Met Ala Thr Asp Ala Ala Leu Arg Arg Leu Leu

AGG	CTG	CAC	CGC	ACG	GAG	ATC	GCG	GTG	GCC	GTG	GAC	AGC	GCC	TTC	CCA	217
Arg	Leu	His	Arg	Thr	Glu	Ile	Ala	Val	Ala	Val	Asp	Ser	Ala	Phe	Pro	
			15					20					25			
CTG	CTG	CAC	GCG	CTG	GCT	GAC	CAC	GAC	GTG	GTC	CCC	GAG	GAC	AAG	TTT	265
Leu	Leu		Ala	Leu	Ala	Asp		Asp	Val	Val	Pro		Asp	Lys	Phe	
		30					35					40				
			amm	03 M	ame	226	C3.3		G3.6				~~ ~			
	GAG															313
GIII	Glu 45	THE	ren	nis	ren	50 50	GIU	ьys	GIU	GIY	55	Pro	GIN	Ala	Pne	
	43					30					55					
CAC	GCC	CTC	CTG	TCC	TGG	CTG	CTG	ACC	CAG	GAC	TCC	ACA	GCC	ATC	CTG	361
	Ala															
60					65					70					75	
GAC	TTC	TGG	AGG	GTG	CTG	TTC	AAG	GAC	TAC	AAC	CTG	GAG	CGC	TAT	GGC	409
Asp	Phe	${\tt Trp}$	Arg	Val	Leu	Phe	Lys	Asp	Tyr	Asn	Leu	Glu	Arg	Tyr	Gly	
				80					85					90		
	CTG															457
Arg	Leu	Gln		Ile	Leu	Asp	Ser		Pro	Lys	Asp	Val	_	Leu	Ser	
			95					100					105			
CAG	ccc	cee	DAA	GGG	AGG	AAG	CCC	CCG	GCC	GTC	CCC	AAG	CCT	ጥጥር	ርጥል	505
	Pro											_				303
		110	-1-			-,-	115					120				
CCG	CCA	ccc	AGA	CTC	ccc	ACC	AAG	AGG	AAG	GCC	TCA	GAA	GAG	GCT	CGA	553
Pro	Pro	Pro	Arg	Leu	Pro	Thr	Lys	Arg	Lys	Ala	Ser	Glu	Glu	Ala	Arg	
	125					130					135					
	GCC															601
	Ala	Ala	Pro	Ala		Leu	Thr	Pro	Arg	_	Thr	Ala	Ser	Pro	-	
140					145					150					155	
ጥርጥ	CAA	ርሞር	AAC	GCC	AAG	רככ	רככ	AAG	AAG	cce	GAG.	AGC	A C C	GCA	GNG	649
	Gln															049
501			_,_	160	2,0			, -	165		014	001	DCI	170	O_L	
CAG	CAG	CGC	CTT	CCA	CTC	GGG	AAC	GGG	ATT	CAG	ACC	ATG	TCA	GCT	TCA	697
Gln	Gln	Arg	Leu	Pro	Leu	Gly	Asn	Gly	Ile	Gln	Thr	Met	Ser	Ala	Ser	
			175					180					185			
	CAG															745
Val	Gln	-	Ala	Val	Ala	Met		Ser	Gly	Asp	Val		Gly	Ala	Arg	
		190					195					200				
GGG	GCC	GTG	GNG	ccc	ΔTC	CTC	δΨC	CAG	CAG	GTG.	սիսեսե	GAG	ጥሮል	GGC	GGC	793
	Ala															193
,	205			1		210					215			3	,	
											_,					
TCC	AAG	AAG	TGC	ATC	CAG	GTT	GGC	GGG	GAG	TTC	TAC	ACT	CCC	AGC	AAG	841
Ser	Lys	Lys	Cys	Ile	Gln	Val	Gly	Gly	Glu	Phe	Tyr	Thr	Pro	Ser	Lys	
220					225					230					235	

TTC G			Ser													889
CCG A		Pro														937
GGA G	ly (985
GCC C Ala L 2																1033
GCC G Ala V 300																1081
CGG G																1129
AGT 0																1177
GTG (1225
ACC (Arg					Glu				1273
CCA Pro						Ala					Thr					1321
CAC					Pro					Lev					Ser	1369
				Pro					l Gly					n Glr	AAC Asn	1417
			Gly					/ Va					y Th		GTG Val	1465

CTG	CGG	TGT	ACT	CAC	TGC	GCC	GCT	GCC	TTC	CAC	TGG	CGC	TGC	CAC	TTC	1513
Leu	Arg	Cys	Thr	His	Cys	Ala	Ala	Ala	Phe	His	Trp	Arg	Cys	His	Phe	
	445					450					455					
CCA	GCC	GGC	ACC	TCC	CGG	CCC	GGG	ACG	GGC	CTG	CGC	TGC	AGA	TCC	TGC	1561
Pro	Ala	Gly	Thr	Ser	Arg	Pro	Gly	Thr	Gly	Leu	Arg	Cys	Arg	Ser	Cys	
460					465					470					475	
TCA	GGA	GAC	GTG	ACC	CCA	GCC	CCT	GTG	GAG	GGG	GTG	CTG	GCC	CCC	AGC	1609
Ser	Gly	Asp	Val	Thr	Pro	Ala	Pro	Val	Glu	Gly	Val	Leu	Ala	Pro	Ser	
				480					485					490		
ccc	GCC	CGC	CTG	GCC	CCT	GGG	CCT	GCC	AAG	GAT	GAC	ACT	GCC	AGT	CAC	1657
Pro	Ala	Arg	Leu	Ala	Pro	Gly	Pro	Ala	Lys	Asp	Asp	Thr	Ala	Ser	His	
			495					500					505			
GAG	CCC	GCT	CTG	CAC	AGG	GAT	GAC	CTG	GAG	TCC	CTT	CTG	AGC	GAG	CAC	1705
Glu	Pro	Ala	Leu	His	Arg	Asp	Asp	Leu	Glu	Ser	Leu	Leu	Ser	Glu	His	
		510					515					520				
ACC	TTC	GAT	GGC	ATC	CTG	CAG	TGG	GCC	ATC	CAG	AGC	ATG	GCC	CGT	CCG	1753
Thr	Phe	Asp	Gly	Ile	Leu	Gln	Trp	Ala	Ile	Gln	Ser	Met	Ala	Arg	Pro	
	525					530					535					
GCG	GCC	CCC	TTC	ccc	TCC	TGA	ccc	CAGAT	rgg (CCGGC	GACA'	rg cz	AGCT	TGA	Г	1804
Ala	Ala	Pro	Phe	Pro	Ser	*										
540					545											
GAG	AGAG:	rgc :	rgag!	AAGG	AC AC	CTC	TTC	C TC	AGTC	CTGG	AAG	CCGG	CCG (CTG	GGATCA	1864
AGA	AGGG	SAC A	AGCG	CAC	CT C	rtgt	CAGT	G CT	GGC:	rgta	AAC	AGCT	CTG :	rgtt:	CTGGG	1924
GAC	ACCA	GCC 1	ATCA!	rgtg	CC TO	GGAA	ATTA	A AC	CTG	ccc	ACT	CTC:	rac :	rctg	GAAGTC	1984
CCC	GGGA	GCC 1	CTC	CTTG	CC TO	GGTG	ACCT	A CT	AAAA	TATA	AAA	AATT	AGC :	rG		2036

(2) INFORMATION FOR SEQ ID NO: 2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 545 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Ala Thr Asp Ala Ala Leu Arg Arg Leu Leu Arg Leu His Arg Thr

Glu Ile Ala Val Ala Val Asp Ser Ala Phe Pro Leu His Ala Leu $20 \hspace{1cm} 25 \hspace{1cm} 30$

Ala Asp His Asp Val Val Pro Glu Asp Lys Phe Gln Glu Thr Leu His 35 40 45

Leu	Lys 50	Glu	Lys	Glu	Gly	Cys 55	Pro	Gln	Ala	Phe	His 60	Ala	Leu	Leu	Ser
Trp 65	Leu	Leu	Thr	Gln	Asp 70	Ser	Thr	Ala	Ile	Leu 75	Asp	Phe	Trp	Arg	Val 80
Leu	Phe	Lys	Asp	Tyr 85	Asn	Leu	Glu	Arg	Tyr 90	Gly	Arg	Leu	Gln	Pro 95	Ile
Leu	Asp	Ser	Phe 100	Pro	Lys	Asp	Val	Asp 105	Leu	Ser	Gln	Pro	Arg 110	Lys	Gly
Arg	Lys	Pro 115	Pro	Ala	Val	Pro	Lys 120	Ala	Leu	Val	Pro	Pro 125	Pro	Arg	Leu
Pro	Thr 130	Lys	Arg	Lys	Ala	Ser 135	Glu	Glu	Ala	Arg	Ala 140	Ala	Ala	Pro	Ala
Ala 145	Leu	Thr	Pro	Arg	Gly 150	Thr	Ala	Ser	Pro	Gly 1 5 5	Ser	Gln	Leu	Lys	Ala 160
Lys	Pro	Pro	Lys	Lys 165	Pro	Glu	Ser	Ser	Ala 170	Glu	Gln	Gln	Arg	Leu 175	Pro
Leu	Gly	Asn	Gly 180	Ile	Gln	Thr	Met	Ser 185	Ala	Ser	Val	Gln	Arg 190	Ala	Val
		195			Asp		200					205			-
	210				Val	215					220				
225					Phe 230					235					240
Ser	Gly	Lys	Asn	Lys 245	Ala	Arg	Ser	Ser	Ser 250	Gly	Pro	Lys	Pro	Leu 255	Val
			260		Gln			265					270		
		275			Ser		280					285			
	290				Lys	295					300				
305					Cys 310					315					320
Ala	Cys	Leu	Ser	Pro 325	Pro	Leu	Arg		Ile 330	Pro	Ser	Gly	Thr	Trp	Arg

Cys Ser Ser Cys Leu Gln Ala Thr Val Gln Glu Val Gln Pro Arg Ala 340 345 350

Glu Glu Pro Arg Pro Gln Glu Pro Pro Val Glu Thr Pro Leu Pro Pro 355 360 365

Gly Leu Arg Ser Ala Gly Glu Glu Val Arg Gly Pro Pro Gly Glu Pro 370 375 380

Leu Ala Gly Met Asp Thr Thr Leu Val Tyr Lys His Leu Pro Ala Pro 385 390 395 400

Pro Ser Ala Ala Pro Leu Pro Gly Leu Asp Ser Ser Ala Leu His Pro 405 410 415

Leu Leu Cys Val Gly Pro Glu Gly Gln Gln Asn Leu Ala Pro Gly Ala
420 425 430

Arg Cys Gly Val Cys Gly Asp Gly Thr Asp Val Leu Arg Cys Thr His 435 440 445

Cys Ala Ala Ala Phe His Trp Arg Cys His Phe Pro Ala Gly Thr Ser 450 455 460

Arg Pro Gly Thr Gly Leu Arg Cys Arg Ser Cys Ser Gly Asp Val Thr 465 470 475 480

Pro Ala Pro Val Glu Gly Val Leu Ala Pro Ser Pro Ala Arg Leu Ala 485 490 495

Pro Gly Pro Ala Lys Asp Asp Thr Ala Ser His Glu Pro Ala Leu His 500 505 510

Arg Asp Asp Leu Glu Ser Leu Leu Ser Glu His Thr Phe Asp Gly Ile 515 520 525

Leu Gln Trp Ala Ile Gln Ser Met Ala Arg Pro Ala Ala Pro Phe Pro 530 540

Ser * 545

- (2) INFORMATION FOR SEQ ID NO: 3:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1545 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

1	ix	١.	FEATURE	•

- (A) NAME/KEY: CDS
- (B) LOCATION: 237..1283
- (D) OTHER INFORMATION:/product= "AIR-2"

(ix) FEATURE:

- (A) NAME/KEY: mat_peptide
 (B) LOCATION:237..1280
- (D) OTHER INFORMATION:/product= "AIR-2"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

AGAG	DAAA	aTG 2	AGGT (TTC	IC AC	GCTC	TTAF	A GAC	CAT	GCG	TTTC	GTCC	CAG	SCT'G'	PACCCG	60
CTGC	TCTC	CAG	CTGGG	ccc	ST GO	GTG	GCCG	G GGC	CGCCC	CTG	CTAT	AGC	CAG (GAGGT	CAA GG	120
ATCO	CACTO	GG 1	AATGO	CATO	GC TC	CATC	TTC	TCC	CCA	SCAT	GGTI	TCT	TAA T	rggg	STAGAA	180
GCAG	GTC	GG I	AGAGA	CCT	CC C1	GGG	CTG	G CCC	CACI	rgcc	CTGT	GAG	GAA (GGGT	rc	236
ATG	TGG	TTG	GTG	TAC	AGT	TCC	GGG	GCC	CCT	GGA	ACG	CAG	CAG	CCT	GCA	284
Met 1	Trp	Leu	Val	Tyr 5	Ser	Ser	Gly	Ala	Pro 10	Gly	Thr	Gln	Gln	Pro 15	Ala	
AGA	AAC	CGG	GTT	TTC	TTC	CCA	ATA	GGG	ATG	GCC	CCG	GGG	GGT	GTC	TGT	332
Arg	Asn	Arg	Val 20	Phe	Phe	Pro	Ile	Gly 25	Met	Ala	Pro	Gly	Gly 30	Val	Cys	
TGG	AGA	CCA	GAT	GGA	TGG	GGA	ACA	GGT	GGT	CAG	GGC	AGA	ATT	TCA	GGC	380
Trp	Arg	Pro	Asp	Gly	Trp	Gly	Thr	Gly	Gly	Gln	Gly	Arg	Ile	Ser	Gly	
		35					40					45				
CCT	GGC	AGC	ATG	GGA	GCA	GGG	CAG	AGA	CTG	GGG	AGT	TCA	GGT	ACC	CAG	428
Pro	Gly	Ser	Met	Gly	Ala		Gln	Arg	Leu	Gly	Ser	Ser	Gly	Thr	Gln	
	50					55					60					
AGA	TGC	TGC	TGG	GGG	AGC	TGT	TTT	GGG	AAG	GAG	GTG	GCT	CTC	AGG	AGG	476
-	Cys	Суѕ	Trp	Gly		Cys	Phe	Gly	Lys		Val	Ala	Leu	Arg	Arg	
65					70					75					80	
GTG	CTG	CAC	ccc	AGC	CCA	GTC	TGC	ATG	GGC	GTC	TCT	TGC	CTG	TGC	CAG	524
Val	Leu	His	Pro		Pro	Val	Cys	Met	_	Val	Ser	Cys	Leu	-	Gln	
				85					90					95		
AAG	AAT	GAG	GAC	GAG	TGT	GCC	GTG	TGT	CGG	GAC	GGC	GGG	GAG	CTC	ATC	572
Lys	Asn	Glu	Asp	Glu	Cys	Ala	Val	Cys	Arg	Asp	Gly	Gly	Glu	Leu	Ile	
			100					105					110			
TGC	TGT	GAC	GGC	TGC	ССТ	CGG	GCC	TTC	CAC	CTG	GCC	TGC	CTG	TCC	CCT	620
Cys	Cys	Asp	Gly	Cys	Pro	Arg	Ala	Phe	His	Leu	Ala	Cys	Leu	Ser	Pro	
		115					120					125				

					CCC											668
Pro		Arg	Glu	IIe	Pro		Gly	Thr	Trp	Arg		Ser	Ser	Cys	Leu	
	130					135					140					
CAG	GCA	ACA	GTC	CAG	GAG	GTG	CAG	ccc	CGG	GCA	GAG	GAG	ccc	CGG	ccc	716
Gln	Ala	Thr	Val	Gln	Glu	Val	Gln	Pro	Arg	Ala	Glu	Glu	Pro	Arg	Pro	
145					150					155					160	
					GAG											764
Gln	Glu	Pro	Pro		Glu	Thr	Pro	Leu		Pro	Gly	Leu	Arg		Ala	
				165					170					175		
GGA	GAG	GAG	GTA	AGA	GGT	CCA	CCT	GGG	GAA	ccc	CTA	GCC	GGC	ATG	GAC	812
					Gly											012
			180					185					190			
					AAG											860
Thr	Thr		Val	Tyr	Lys	His		Pro	Ala	Pro	Pro		Ala	Ala	Pro	
		195					200					205				
CTG	CCA	GGG	CTG	GAC	TCC	TCG	GCC	CTG	CAC	ccc	СТА	CTG	тст	GTG	GGT	. 908
					Ser											. 305
	210	_				215					220		-		-	
CCT	GAG	GGT	CAG	CAG	AAC	CTG	GCT	CCT	GGT	GCG	CGT	TGC	GGG	GTG	TGC	956
	Glu	Gly	Gln	Gln	Asn	Leu	Ala	Pro	Gly		Arg	Cys	Gly	Val	. •	
225					230					235					240	
GGA	GAT	GGT	ACG	GAC	GTG	CTG	CGG	TGT	ACT	CAC	TGC	GCC	GCT	GCC	TTC	1004
					Val											
				245					250					255		
					TTC											1052
His	Trp	Arg	_	His	Phe	Pro	Ala		Thr	Ser	Arg	Pro		Thr	Gly	
			260					265					270			
CTG	CGC	TGC	AGA	TCC	TGC	TCA	GGA	GAC	GTG	ACC	CCA	GCC	CCT	GTG	GAG	1100
					Cys											1100
		275					280					285				
					AGC											1148
Gly		Leu	Ala	Pro	Ser	Pro 295	Ala	Arg	Leu	Ala	Pro 300	Gly	Pro	Ala	Lys	
	290					293					300					
GAT	GAC	ACT	GCC	AGT	CAC	GAG	ccc	GCT	CTG	CAC	AGG	GAT	GAC	CTG	GAG	1196
					His											
305					310					315					320	
					CAC											1244
Ser	Leu	Leu	Ser		His	Thr	rne	Asp	_	тТе	Leu	Gln	Trp		Ile	
				325					330					335		
CAG	AGC	ATG	GCC	CGT	CCG	GCG	GCC	ccc	TTC	ccc	TCC	TGA	CCC	CAGA'	TGG	1293
					Pro										•	
			340					345								

CCG	GAC/	ATG (CAGC:	rctg/	AT G	AGAG	AGTGG	TG	AGAA	GGAC	ACC:	CCT	rcc :	TCAGI	CCTGG
AAGO	CGGC	CCG (GCTG	GGATO	CA AC	GAAG	GGA	CAG	CGCCI	ACCT	CTT	STCAC	GTG (CTCG	SC TG TA
AACA	GCT	CTG :	rg tt :	rctgo	G G	ACAC	CAGCO	ATC	CATG	rgcc	TGG	TAAF	CAA .	ACCCI	r gcc cc
ACTI	CTC	rac :	rctgo	GAAGT	rc co	ccec	GAGCO	C TC	CCT	rgcc	TGGT	rgaco	CTA (CTAAZ	\AATAT
AAAA	ATTA	AGC :	rg												
(2)	IN	FOR	MAT:	ION	FOF	SE	Q I	D NO); 4	! :					
		(i		-			ARA								
			(B)	TY	PE:	am	348 ino	ac:	id	aci	ds				
			(D)	TC	POL	. OGY	: 1:	inea	ar						
							: p: RIP			SEQ	ID	NO:	4:		
Met 1	Trp	Leu	Val	Tyr 5	Ser	Ser	Gly	Ala	Pro 10	Gly	Thr	Gln	Gln	Pro 15	Ala
Arg	Asn	Arg	Val 20	Phe	Phe	Pro	Ile	Gly 25	Met	Ala	Pro	Gly	Gly 30	Val	Cys
Trp	Arg	Pro 35	Asp	Gly	Trp	Gly	Thr 40	Gly	Gly	Gln	Gly	Arg 45	Ile	Ser	Gly
Pro	Gly 50	Ser	Met	Gly	Ala	Gly 55	Gln	Arg	Leu	Gly	Ser 60	Ser	Gly	Thr	Gln
Arg 65	Cys	Cys	Trp	Gly	Ser 70	Cys	Phe	Gly	Lys	Glu 75	Val	Ala	Leu	Arg	Arg 80
Val	Leu	His	Pro	Ser 85	Pro	Val	Cys	Met	Gly 90	Val	Ser	Cys	Leu	Cys 95	Gln
Lys	Asn	Glu	Asp 100	Glu	Cys	Ala	Val	Cys 105	Arg	Asp	Gly	Gly	Glu 110	Leu	Ile
Cys	Cys	Asp 115	Gly	Cys	Pro	Arg	Ala 120	Phe	His	Leu	Ala	Cys 125	Leu	Ser	Pro
Pro	Leu 130	Arg	Glu	Ile	Pro	Ser 135	Gly	Thr	Trp	Arg	Cys 140	Ser	Ser	Cys	Leu
Gln 145	Ala	Thr	Val	Gln	Glu 150	Val	Gln	Pro	Arg	Ala 155	Glu	Glu	Pro	Arg	Pro 160

Gln Glu Pro Pro Val Glu Thr Pro Leu Pro Pro Gly Leu Arg Ser Ala 165 170 175

Gly Glu Glu Val Arg Gly Pro Pro Gly Glu Pro Leu Ala Gly Met Asp 180 185 190

Thr Thr Leu Val Tyr Lys His Leu Pro Ala Pro Pro Ser Ala Ala Pro 195 200 205

Leu Pro Gly Leu Asp Ser Ser Ala Leu His Pro Leu Leu Cys Val Gly 210 215 220

Pro Glu Gly Gln Gln Asn Leu Ala Pro Gly Ala Arg Cys Gly Val Cys 225 230 235 240

Gly Asp Gly Thr Asp Val Leu Arg Cys Thr His Cys Ala Ala Ala Phe 245 250 255

His Trp Arg Cys His Phe Pro Ala Gly Thr Ser Arg Pro Gly Thr Gly 260 265 270

Leu Arg Cys Arg Ser Cys Ser Gly Asp Val Thr Pro Ala Pro Val Glu \$275\$

Gly Val Leu Ala Pro Ser Pro Ala Arg Leu Ala Pro Gly Pro Ala Lys 290 295 300

Asp Asp Thr Ala Ser His Glu Pro Ala Leu His Arg Asp Asp Leu Glu 305 310 315 320

Ser Leu Leu Ser Glu His Thr Phe Asp Gly Ile Leu Gln Trp Ala Ile 325 330 335

Gln Ser Met Ala Arg Pro Ala Ala Pro Phe Pro Ser $\,\,\star\,\,$ 340 $\,\,$ 345

(2) INFORMATION FOR SEQ ID NO: 5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1463 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION:237..1001
- (D) OTHER INFORMATION:/product= "AIR-3"

(ix) FEATURE:

- (A) NAME/KEY: mat peptide
- (B) LOCATION: 237..998
- (D) OTHER INFORMATION:/product= "AIR-3"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: AGAGAAAGTG AGGTCTTCTC AGGCTCTTAA GAGCATGGCG TTTGGTCCAG GCTGTACCCG CTGCTCTCAG CTGGGCCCGT GGGTGGGCCG GGCGCCCCTG CTATAGCCAG GAGGTCAAGG 120 ATCCACTGGG AATGCCATGC TCATCTTTCG TCCCCAGCAT GGTTTCTTAA TGGGGTAGAA 180 GCAGGTCGGG AGAGACCTCC CTGGGCCTGG CCCCACTGCC CTGTGAGGAA GGGTTC 236 ATG TGG TTG GTG TAC AGT TCC GGG GCC CCT GGA ACG CAG CAG CCT GCA Met Trp Leu Val Tyr Ser Ser Gly Ala Pro Gly Thr Gln Gln Pro Ala 10 AGA AAC CGG GTT TTC TTC CCA ATA GGG ATG GCC CCG GGG GGT GTC TGT Arg Asn Arg Val Phe Phe Pro Ile Gly Met Ala Pro Gly Gly Val Cys 20 25 TGG AGA CCA GAT GGA TGG GGA ACA GGT GGT CAG GGC AGA ATT TCA GGC Trp Arg Pro Asp Gly Trp Gly Thr Gly Gly Gln Gly Arg Ile Ser Gly 40 35 CCT GGC AGC ATG GGA GCA GGG CAG AGA CTG GGG AGT TCA GGT ACC CAG 428 Pro Gly Ser Met Gly Ala Gly Gln Arg Leu Gly Ser Ser Gly Thr Gln 55 50 AGA TGC TGC TGG GGG AGC TGT TTT GGG AAG GAG GTG GCT CTC AGG AGG Arg Cys Cys Trp Gly Ser Cys Phe Gly Lys Glu Val Ala Leu Arg Arg 70 GTG CTG CAC CCC AGC CCA GTC TGC ATG GGC GTC TCT TGC CTG TGC CAG 524 Val Leu His Pro Ser Pro Val Cys Met Gly Val Ser Cys Leu Cys Gln 85 90 AAG AAT GAG GAC GAG TGT GCC GTG TGT CGG GAC GGC GGG GAG CTC ATC 572 Lys Asn Glu Asp Glu Cys Ala Val Cys Arg Asp Gly Glu Leu Ile 105 TGC TGT GAC GGC TGC CCT CGG GCC TTC CAC CTG GCC TGC CTG TCC CCT 620 Cys Cys Asp Gly Cys Pro Arg Ala Phe His Leu Ala Cys Leu Ser Pro 120 CCG CTC CGG GAG ATC CCC AGT GGG ACC TGG AGG TGC TCC AGC TGC CTG Pro Leu Arg Glu Ile Pro Ser Gly Thr Trp Arg Cys Ser Ser Cys Leu 130 135 140 CAG GCA ACA GTC CAG GAG GTG CAG CCC CGG GCA GAG GAG CCC CGG CCC 716 Gln Ala Thr Val Gln Glu Val Gln Pro Arg Ala Glu Glu Pro Arg Pro 145 150 CAG GAG CCA CCC GTG GAG ACC CCG CTC CCC CCG GGG CTT AGG TCG GCG Gln Glu Pro Pro Val Glu Thr Pro Leu Pro Pro Gly Leu Arg Ser Ala

170

165

GGA	GAG	GAG	ccc	CGC	TGC	CAG	GGC	TGG	ACT	CCT	CGG	CCC	TGC	ACC	CCC	812
Gly	Glu	Glu	Pro	Arg	Cys	Gln	Gly	\mathtt{Trp}	Thr	Pro	Arg	Pro	Cys	Thr	Pro	
			180					185					190			
ጥአሮ	an Can	CTC	TGG	CTC	СТС	7,CC	CTC	N.C.C	7.67	NCC.	TCC	CTC	CTC	cmc	ccc	860
			Trp													860
ı yı	Cys	195	115	• • • •	200	9	200	561	my	****	1	205	пец	val	ALY	
GTT	GCG	GGG	TGT	GCG	GAG	ATG	GTA	CGG	ACG	TGC	TGC	GGT	GTA	CTC	ACT	908
Val	Ala	Gly	Cys	Ala	Glu	Met	Val	Arg	Thr	Cys	Cys	Gly	Val	Leu	Thr	
	210					215					220					
			CCT													956
	Pro	Leu	Pro	ser		GTA	Ala	Ala	Thr		Gin	Pro	Ala	Pro		
225					230					235					240	
GGC	CCG	GGA	CGG	GCC	TGC	GCT	GCA	GAT	CCT	GCT	CAG	GAG	ACG	TGA		1001
			Arg													
_		_	_	245	_			_	250					255		
ccc	CAGC	ccc :	rgtgo	GAGG	GG G	FGCT	GCC	CCZ	AGCC	CCGC	CCG	CCTG	GCC (CCTG	GCCTG	1061
CCA	AGGA'	rga (CACTO	5CCA(ST C	ACGA	3CCC(3 CT	CTGC	ACAG	GGA'	rgac(CTG (GAGT(CCCTTC	1121
ጥርልና	CGAC	SCA (ראככי	rrcei	ልጥ ቤ	CATO	്ന്നുദ	- AG	recei	таээ	CCA	BAGC:	ATG (ברררו	STCCGG	1181
1011	300770		01100								0011	J. 100			310000	1101
CGG	cccc	CTT (cccc	rccre	GA C	CCCA	GATG	G CC	GGGA	CATG	CAG	CTCT	GAT (GAGA	GAGTGC	1241
TGA	GAAG	GAC 2	ACCT	CCTT	CC T	CAGT	CCTG	G AA	GCCG	GCCG	GCT	GGGA'	rca .	AGAA	GGG AC	1301
AGC	GCCA(CCT	CTTG:	rcag'	rg C'	rcgg	CTGT	A AAG	CAGC'	TCTG	TGT'	TTCT	GGG (GACA	CCAGCC	1361
አ ምሮ፣	ነጥርም(ברר י	TCGA	ል አ ተኮጥ የ	וב בב	ררייים	3000	יי אַריי	اشاباليل	ሮሞልሮ	اشاش	CDA	י אתב	ררני	GGAGCC	1421
*** 01	7101/		. GGM		a a			o no	. 1 0 1	CIAC	101	JOHN	010		CONGCC	1471
TCT	CTT	GCC '	TGGT	GACC'	ra c'	TAAA	ATA	r aa	ааат'	TAGC	TG					1463

(2) INFORMATION FOR SEQ ID NO: 6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 254 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Met Trp Leu Val Tyr Ser Ser Gly Ala Pro Gly Thr Gln Gln Pro Ala 1 5 10 15

Arg Asn Arg Val Phe Phe Pro Ile Gly Met Ala Pro Gly Gly Val Cys $20 \hspace{1.5cm} 25 \hspace{1.5cm} 30$

Trp Arg Pro Asp Gly Trp Gly Thr Gly Gly Gln Gly Arg Ile Ser Gly 35 \$40\$

Pro Gly	Ser	Met	Gly	Ala	Gly	Gln	Arg	Leu	Gly	Ser	Ser	Gly	Thr	Gln
50					55					60				

- Arg Cys Cys Trp Gly Ser Cys Phe Gly Lys Glu Val Ala Leu Arg Arg 65 70 75 80
- Val Leu His Pro Ser Pro Val Cys Met Gly Val Ser Cys Leu Cys Gln 85 90 95
- Lys Asn Glu Asp Glu Cys Ala Val Cys Arg Asp Gly Gly Glu Leu Ile 100 105 110
- Cys Cys Asp Gly Cys Pro Arg Ala Phe His Leu Ala Cys Leu Ser Pro 115 120 125
- Pro Leu Arg Glu Ile Pro Ser Gly Thr Trp Arg Cys Ser Ser Cys Leu 130 135 140
- Gln Glu Pro Pro Val Glu Thr Pro Leu Pro Pro Gly Leu Arg Ser Ala 165 170 175
- Gly Glu Glu Pro Arg Cys Gln Gly Trp Thr Pro Arg Pro Cys Thr Pro 180 185 190
- Tyr Cys Val Trp Val Leu Arg Val Ser Arg Thr Trp Leu Leu Val Arg 195 200 205
- Val Ala Gly Cys Ala Glu Met Val Arg Thr Cys Cys Gly Val Leu Thr 210 215 220
- Ala Pro Leu Pro Ser Thr Gly Ala Ala Thr Ser Gln Pro Ala Pro Pro 225 230 230 235
- Gly Pro Gly Arg Ala Cys Ala Ala Asp Pro Ala Gln Glu Thr *
 245 250 250

(2) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

(2) INFOR	MATION FOR SEQ ID NO: 8:	
(i) :	SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO: 8:	
GTTCCCGAGT 6	GGAAGGCGCT GC	22
(2) INFOR	MATION FOR SEQ ID NO: 9:	
(i) :	SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO: 9:	
AGGGGACAGG (CAGGCCAGGT	20
(2) INFOR	MATION FOR SEQ ID NO: 10:	
(i) :	SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO: 10:	
GAGTTCAGGT A	ACCCAGAGAT GCTG	24
(2) INFOR	MATION FOR SEQ ID NO: 11:	
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO: 11:	
CTCGCTCAGA A	AGGGACTCCA	20

(2) INFORMATION FOR SEQ ID NO: 12:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:	
GGATTCAGAC CATGTCAGCT TCA	23
(2) INFORMATION FOR SEQ ID NO: 13:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:	
GTGCTGTTCA AGGACTACAA C	21
(2) INFORMATION FOR SEQ ID NO: 14:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:	
TGGATGAGGA TCCCCTCCAC G	21
(2) INFORMATION FOR SEQ ID NO: 15:	
(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 27 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:	
CCATCCTAAT ACGACTCACT ATAGGGC	27

(2) INFORMATION FOR SEQ ID NO: 16:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:	
TGCAGGCTGT GGGAACTCCA	20
(2) INFORMATION FOR SEQ ID NO: 17:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:	
AGAAAAAGAG CTGTACCCTG TG	2 2
(2) INFORMATION FOR SEQ ID NO: 18:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:	
TGCAAGGAAG AGGGGCGTCA GC	22
(2) INFORMATION FOR SEQ ID NO: 19:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:	
TCCACCACAA GCCGAGGAGA T	21

(2)	INFO	RMATION FOR SEQ ID NO: 20:	
	(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO: 20:	
ACGG	GCTCCT	CAAACACCAC T	21
(2)	INFO	RMATION FOR SEQ ID NO: 21:	
	(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO: 21:	
TGGA	GATGGG	CAGGCCGCAG GGTG	24
(2)	INFO	RMATION FOR SEQ ID NO: 22:	
	(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO: 22:	
CAGT	CCAGCT	GGGCTGAGCA GGTG	24
(2)	INFO	RMATION FOR SEQ ID NO: 23:	
	(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO: 23:	

GCGGCTCCAA GAAGTGCATC CAGG

- (2) INFORMATION FOR SEQ ID NO: 24:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

CTCCACCCTG CAAGGAAGAG GGGC

24

- (2) INFORMATION FOR SEQ ID NO: 25:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: peptide
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

Thr Leu His Leu Lys Glu Lys Glu Gly Cys Pro Gln Ala Phe His 1 5 10 15

- (2) INFORMATION FOR SEQ ID NO: 26:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: peptide
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

Gly Lys Asn Lys Ala Arg Ser Ser Ser Gly Pro Lys Pro Leu Val 1 5 10 15

- (2) INFORMATION FOR SEQ ID NO: 27:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

ATGGCGACGG ACGCGGCGCT ACGC

- (2) INFORMATION FOR SEQ ID NO: 28:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

CCTGGATGTA CTTCTTGGAG CCGC

- (2) INFORMATION FOR SEQ ID NO: 29:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

GAGCCCGAGG GGCCGTGGAG GGGA

- (2) INFORMATION FOR SEQ ID NO: 30:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

GGCTGCACCT CCTGGACTGT TGCC

- (2) INFORMATION FOR SEQ ID NO: 31:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

GATCCTGCTC AGGAGACGTG ACCC

- (2) INFORMATION FOR SEQ ID NO: 32:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

CACCAGGCAA GGAGAGGCTC CCGG

- (2) INFORMATION FOR SEQ ID NO: 33:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

CCACCCCATG GCGACGGACG

- (2) INFORMATION FOR SEQ ID NO: 34:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

GGAATTCGGA GGGGAAGGGG GCCGCCGGA

- (2) INFORMATION FOR SEQ ID NO: 35:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

GGACTGAGGA AGGAGGTGTC CTTC

- 2) INFORMATION FOR SEQ ID NO: 36:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: peptide
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

Asp Gly Ile Leu Gln Trp Ala Ile Gln Ser Met Ala Arg Pro Ala Ala Pro Phe Pro Ser 1 5 10 15 20



10

15

20

25

30

35

Claims

- 1. An isolated DNA sequence characterized by comprising the sequence id. no. 1 or a functional fragment or variant thereof encoding a protein having the same functional activity, or an functionally equivalent isolated DNA sequence hybridizable thereto.
- 2. An isolated DNA sequence according to claim 1, characterized in that it is associated with diseases related to immune maturation and regulation of immune response towards self and nonself, such as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).
- 3. An isolated DNA-sequence according to claim 1 or 2, characterized in that it includes a gene defect responsible for APECED.
- 4. A DNA sequence according to claim 1, characterized by having the sequence according to sequence id. no 1 or a functional fragment thereof having the sequence according to sequence id. no 3 or sequence id. no 5.
- 5. A protein characterized by comprising the amino acid sequence id. no. 2 or a functional fragment or variant thereof having the same functional properties.
- 6. A protein according to claim 5, characterized in that it is associated diseases related to immune maturation and regulation of immune response towards self and nonself, such as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).
- 7. A protein according to claim 5 or 6, characterized by having the amino acid sequence id. no. 2, or a functional fragment thereof having the sequence according to sequence id. no. 4, or a functional fragment thereof having the sequence according to sequence id. no 6.
- 8. A protein according to any of claims 5 to 7, characterized by having distinct structural motifs, including the PHD finger motif (PHD), the LXXLL motif (L), proline-rich region (PRR), and cystein-rich region (CRR).
- 9. A method for the diagnosis of diseases related to immune maturation and regulation of immune response towards self and nonself, characterized by detecting in a biological specimen the presence of a DNA sequence comprising the sequence id. no. 1 or a functional fragment or variant thereof encoding a protein having the same functional activity, or a functionally equivalent isolated DNA-sequence hybridizable thereto.

10

15

20

25

30

35


- 10. A method according to claim 9, characterized in that the DNA sequence is associated with APECED.
- 11. A method according to claim 9 or 10, characterized in that the DNA sequence includes a gene defect responsible for APECED.
- 12. A method according to claim 11, characterized in that the gene defect to be detected includes a "C" to "T" transition resulting in the "Arg" to "Stop" nonsense mutation at amino acid position 257 and/or a "A" to "G" transversion resulting in the "Lys" to "Glu" missense mutation at amino acid position 42.
- 13. A method according to any one of claims 9 to 12, characterized in that DNA techniques are used for the detection.
- 14. A method according to any one of claims 9 to 13, characterized in that the detection takes advantage of Taql or another enzyme cleaving at recognition site 5'-TCGA-3' digestion.
- 15. A method according to any one of claims 9 to 14, characterized in that the disease is autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).
- 16. A method for the diagnosis of diseases related to immune maturation and regulation of immune response towards self and nonself, characterized by detecting in a biological specimen the presence or the absence of a protein comprising the sequence id. no. 2, or a functional fragment thereof having the sequence according to sequence id. no. 4, or a functional fragment thereof having the sequence according to sequence id. no. 6.
- 17. A method according to claim 16, characterized in that the protein is associated with APECED.
- 18. A method according to claim 16 or 17, characterized in that the disease is autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).
- 19. The use of the DNA sequence according to any one of claims 1 to 4 in the diagnosis of diseases related to immune maturation and regulation of immune response towards self and nonself, such as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).


10

15

- 20. The use of the protein according to any one of claims 5 to 7 in the diagnosis of diseases related to immune maturation and regulation of immune response towards self and nonself, such as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).
- 21. The use of the DNA sequence according to any one of claims 1 to 4 for the preparation of a medicament useful in a gene therapy method of diseases related to immune maturation and regulation of immune response towards self and nonself, such as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).
- 22. The use of the DNA sequence according to any one of claims 1 to 4 in the treatment of diseases related to immune maturation and regulation of immune response towards self and nonself, such as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).
- 23. Reagents reacting with the DNA sequence according to any one of claims 1 to 4 or the protein of any one of the claims 5 to 8 or with reagents reacting therewith.
- 24. Reagents according to claim 23, characterized in that they are antibodies.

1/10








FIG. 3

4/10





FIG. 4


FIG. 5


AIK-I: 434 .GGIDVLK.IH.AAWK.HF.AGISK.GIGLK 4/5
--

6/10




7/10





9/10



10/10




FIG.

Attome	y's Decket No	U 012653-9	PATENT
	COMBINED DE	CLARATION AND POV	VER OF ATTORNEY
(ORIG	INAL, DESIGN, NA	TIONAL STAGE OF PCT, S CONTINUATION OR C-I	SUPPLEMENTAL, DIVISIONAL, -P)
As a be	elow named invento	or, I hereby declare that:	
		TYPE OF DECLARATI	ON
This decia	aration is of the fol	iowing type:	
	(check one applicable item	below)
	onginal.		
	design.		
	supplemental.		
		, .	ing filed as a divisional, continuation or theck appropriate one of last three items.
\mathbf{X}	national stage of	PCT.	
	one of the following 3 in CONTINUATION OR C-I		to attach ADDED PAGES FOR DIVISIONAL,
	divisional.		
	continuation.		
Ξ	continuation-in-pa	art (C-I-P).	
	IN1	VENTORSHIP IDENTIFI	CATION
WARNING			iarms, an explanation of the facts, including ad invention was made, should be submitted
l believe t an origina	that I am the ongin II, first and joint in	al, first and sole inventor (i	as stated below, next to my name f only one name is listed below) or listed below) of the subject matter ne invention entitled:
		TITLE OF INVENTIO	ON
Novel	aene defective	in apeced and its use	9
	<i>y</i>		

(Declaration and Power of Attorney [1-1]-page 1 of 5)



SPECIFICATION IDENTIFICATION

the specification of which:
(complete (a), (b) or (c))
(a) Is attached hereto.
(b) was filed on as _ Senal No. 0 / or _ Express Mail No., as Senal No. not yet known and was amended on (if applicable).
NOTE Amendments filed after the original papers are deposited with the PTO that contain new matter are not accorded a filing date by being referred to in the declaration. Accordingly, the amendments involved are those filed with the application papers or, in the case of a supplemental declaration, are those amendments claiming matter not encompassed in the original statement of invention or claims. See 37 CFR 1.67
(c) \overline{X} was described and claimed in PCT International Application No. PCT/F198/00749 filed on 23 Sept. 1998 and as amended under PCT Article 19 on (if any).
ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR
I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.
I acknowledge the duty to disclose information, which is material to patentability as defined in 37. Code of Federal Regulations, § 1.56,
(also check the following items, if desired)
and which is material to the examination of this application, namely, information where there is a substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent, and
in compliance with this duty, there is attached an information disclosure statement, in accordance with 37 CFR 1.98.
PRIORITY CLAIM (35 U.S.C. § 119(a)-(d))
I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)–(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.
(complete (d) or (e))
(d) no such applications have been filed.
(e) 🖔 such applications have been filed as follows.
NOTE Where item (c) is entered above and the International Application which designated the U.S. itself claimed priority check item (e), enter the details below and make the priority claim.

(Declaration and Power of Attorney [1-1]-page 2 of 6)



PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS APPLICATION AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. § 119(a)-(d)

COUNTRY (OR INDICATE IF PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 37 USC 119
FI	973762	23 Sept. 1997	X YES NO T
			TYES NOT
			TYES NO T
			TYES NO T
			TYES NO T

CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S) (34 U.S.C. § 119(e))

i hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

PROVISI	IONAL APPLICATION NUMBER	FILING DATE
	/	
	/	
	1	

CLAIM FOR BENEFIT OF EARLIER US/PCT APPLICATION(S) UNDER 35 U.S.C. 120

_	The claim for the benefit of any such applications are set forth in the
	attached ADDED PAGES TO COMBINED DECLARATION AND POWER OF
	ATTORNEY FOR DIVISIONAL, CONTINUATION OR CONTINUATION-IN
	PART (C-I-P) APPLICATION.

(Declaration and Power of Attorney [1-1]-page 3 of 6)

ALL F	FOREIGN APPLICATION(S), IF A (6 MONTHS FOR DESIGN) PRIO	NY, FILED MORE THAN 12 MONTHS PR TO THIS U.S. APPLICATION
NOTE.	the basis for this application entering the Unite divisional, or continuation-in-part, then also co	in the filing date of this application is a PCT filing forming ad States as (1) the national stage, or (2) a continuation, implete ADDED PAGES TO COMBINED DECLARATION L. CONTINUATION OR C-I-P APPLICATION for benefit 35 U.S.C. § 120.
	POWER OF	ATTORNEY
	eby appoint the following attomey(s) ansact all business in the Patent and T	and/or agent(s) to prosecute this application rademark Office connected therewith.
	(list name and reg	istration number)
JO JO JO RJC AL	UL B WEST. 18947 SEPH H. HANDELMAN, 26179 HN RICHARDS, 31053 HN J CHRYSTAL, 26360 CHARD J STREIT, 25765 AN K ROBERTS, 1777 DELVALLE GOLDSMITH, 14383 (check the following	PETER D. GALLOWAY, 27885 LAIN C. BAILLIE, 24090— THOMAS F. PETERSON, 24790. RICHARD P. BERG, 28145. JULIAN H. COHEN, 20302 WILLIAM R. EVANS, 25858 JANET I. CORD, 33778 CLIFFORD J. MASS, 30086
	teries, the length is	y nam, w approxim
		on and power of attorney, is the authorization to accept and follow instructions from my
SEND (CORRESPONDENCE TO	DIRECT TELEPHONE CALLS TO. (Name and telephone number)
2	ADAS & PARRY S WEST 61ST STREET EW YORK, NEW YORK 10023	(212)708-1930

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(Declaration and Power of Attorney [1-1]-page 4 of 6)



(cneck proper poxies) for any of the following added page(s) that form a part of this declaration)

$\overline{\mathbf{x}}$	Signature for fourth and subsequent joint inventors. Number of pages added
	• • •
Ξ	Signature by administrator(trix), executor(trix) or legal representative for deceased or incapacitated inventor. Number of pages added
	• • •
=	Signature for inventor who refuses to sign or cannot be reached by person authorized under 37 CFR 1.47. Number of pages added
=	Added page for signature by one joint inventor on behalf of deceased inventor(s) where legal representative cannot be appointed in time. (37 CFR 1 47)
=	Added pages to combined declaration and power of attorney for divisional, continuation, or continuation-in-part (C-I-P) application.
	Number of pages added
=	Authorization of attorney(s) to accept and follow instructions from representative.
	(if no further pages form a part of this Declaration, then end this Declaration with this page and check the following item)
	This declaration ends with this page.

(Declaration and Power of Attorney [1-1]—page 6 of 6)

SIGNATURE(S)

NOTE Carefully indicate the family (or last) name, as it should appear on the filing receipt and all other documents.

60	Full name of sole or first inventor Kai	Krohn
VY	(GIVEN NAME) (MIDDLE INITIAL OR NAME)	FAMILY (OR LAST NAME)
	Inventor's signature	
	Date 2.3: 2000 Country of Citizenship	Finland
	Residence Salutin taautie 751	FIX
	Post Office Address 36450 SATUENTAG	LA
	Full name of second joint inventor, if any	
110	Maarit	Heino
	(GIVEN NAME) (MIDDLE INITIAL OR NAME)	FAMILY (OR LAST MAME)
	Inventor's signature	
	Date 2.3. 2000 Country of Citizenship	Finland
	Residence Kaskitie 6 1 94	<u>FL</u>
	Post Office Address 33540 TA	
	Full name of third joint inventor, if any	
2 10	Pärt	Peterson
1 10	IGIVEN NAME) IMIDOLE HATTAL OR NAME)	FAMILY FOR LAST NAME
ろ	D imple	
ゔ゙	Inventor's signature	
ゔ゙		Estonia
ゔ゙	Inventor's signature	Estonia (5)×

(Declaration and Power of Attorney [1-1]-page 5 of 6)

-7

Attorney's Docket No. U 012653-9

ADDED PAGE TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR SIGNATURE BY FOURTH AND SUBSEQUENT INVENTORS

Full name of fourth joint in	ventor, if any	
Hamıs <u>h</u>	<u> </u>	Scott
GIVEN NAME	MIDDLE INITIAL OR HAME	FAMILY (OR LAST NAME)
Inventor's signature	Humah Jeol	
Date	Country of Citizenship	Australia
Residence	LINIFIGHER CARGENS	AUX
Post Office Address	RUNSVICK 19157	
VIC Drid	3057 AUSTULIA	
Full name of fifth joint inve	entor, if any	
Stylianos	•	Antonarakıs
GIVEN NAME	MIDDLE INTTAL OR NAME	FAMILY (OR LAST NAME)
inventor's signature		
Data	Courter of Citizonahua	US/Greece
Date	Country of Citizenship.	
Residence	Country of Citizenship .	
_		
Residence		
Residence Post Office Address		
Post Office Address Full name of sixth joint inv	ventor, if any	lalıoti .
Post Office Address	ventor, if any	
Post Office Address Full name of sixth joint into	ventor, if any MIDOLE INITIAL OR NAME Lapui Cu	Lalioti . FAMILY (OR LAST NAME)
Post Office Address Full name of sixth joint int Maria GIVEN NAME	ventor, if any MIDOLE INITIAL OR NAME Lapui Cu	Lalioti . FAMILY (OR LAST NAME)
Post Office Address Full name of sixth joint int Mar 1a GIVEN NAME Inventor's signature	ventor, if any	Lalioti FAMILY FOR LAST NAME SREECE
Post Office Address Full name of sixth joint in Maria GIVEN NAME Inventor's signature Date 10-10-00	Country of Citizenship	Lalioti FAMILY (OR LAST NAME) SREECE

EDGBASTON

Post Office Address.

Residence __

Full name of sixth joint inventor, if any

79

ABINED DECLARATION AND POWER OF E BY FOURTH AND SUBSEQUENT INVENTO if any Scott MIDDLE INITIAL OR NAME FAMILY (OR LAST NAME Country of Citizenship Australia
if any Scott MIDDLE INITIAL OR NAME Country of Citizenship Australia
if any Scott MIDDLE INITIAL OR NAME Country of Citizenship Australia
if any Scott MIDDLE INITIAL OR NAME FAMILY (OR LAST NAME Country of Citizenship Australia
MIDDLE INITIAL OR NAME FAMILY (OR LAST NAME Country of Citizenship Australia
Country of Citizenship Australia
Country of Citizenship Australia

Maria

GIVEN NAME

Inventor's signature

Date 18-10-00

Country of Citizenship

GREECE

STOCKDALE

Country of Citizenship US/Greece

Post Office Address BIRMINGHAM UN BIS 3XH

5W122819M

SIGNATURE(S)

NOTE. Carefully indicate the family (or last) name, as it should appear on the filing receipt and all other documents.

Full name of sole or firs	t inventor	
Kai		Krohn
(GIVEN HAME)	(MIDDLE INITIAL OR NAME)	FAMILY (OR LAST NAME)
Inventor's signature		
Date	Country of Citizenship _	Finland
Post Office Address	·	
Full name of second join	nt inventor, if any	11-2
Maarit	(MIDDLE INITIAL OR NAME)	Heino FAMILY (OR LAST NAME)
(GIVEN NAME)		PARKET (UN EAST RAIRE)
Inventor's signature		Finland
Date	Country of Citizenship _	1 1111ai/u
Residence		
Post Office Address		
	-	
Full name of third joint	inventor, if any	
Pärt		Peterson
(GIVEN NAME)	(MIDOLE INITIAL OR NAME)	FAMILY (OR LAST NAME)
inventor's signature		Estonia
Date	Country of Citizenship _	ratuilla
Date		

(Declaration and Power of Attorney [1-1]—page 5 of 6)

(check proper box(es) for any of the following added page(s) that form a part of this declaration)

\overline{X}	Signature for fourth and subsequent joint inventors. Number of pages added 2
=	Signature by administrator(trix), executor(trix) or legal representative for deceased or incapacitated inventor. Number of pages added
	•••
=	Signature for inventor who refuses to sign or cannot be reached by person authorized under 37 CFR 1.47. Number of pages added
	• • •
=	Added page for signature by one joint inventor on behalf of deceased inventor(s) where legal representative cannot be appointed in time. (37 CFR 1.47)
	· · ·
_	Added pages to combined declaration and power of attorney for divisional, continuation, or continuation-in-part (C-I-P) application.
	Number of pages added
_	Authorization of attorney(s) to accept and follow instructions from representative.
	(if no further pages form a part of this Declaration, then end this Declaration with this page and check the following item)
	This declaration ends with this page.

(Deciaration and Power of Attorney [1-1]-page 6 of 6)

Attorney's Docket No	•	
	-	
ADDED BACK 3	TO COMBINED DECLARATION	i tain nottien on
	NATURE BY FOURTH AND SU	
THE OWNER TOWN	THE DITIONAL MAD BO	DSEQUENT INVENTOR
Full name of 7th joint	inventor, if any	
Nobuyoshı	MIDDLE INITIAL OR NAME .	Shimizu
GIVEN NAME		FAMILY (OR LAST NAME)
		3
Date	Country of Citizenship	Japan
Residence		~
Post Office Address		
Full name of 8thjoint in	ventor if any	-
Jun	, omen, a un,	Kudoh
GIVEN NAME	MIDDLE INITIAL OR NAME	FAMILY (OR LAST NAME)
Inventor's signature		
	Country of Citizenship	7
Residence	•	
- 031 Office A00.033		
	Page 2 And Share and	
Eulianea at Othinia i		
Full name of 9th joint in	пченцог, и алу	
CIVEN NAME	MIDDLE INCOAL OR NAME	FAMILY (OR LAST NAME)

Inventor's signature _____

Residence ______
Post Office Address __

Date _____ Country of Citizenship ___

Attamey's Decket No.	U 012653-9	_ PATENT
COMBINED DE	ECLARATION AND POV	WER OF ATTORNEY
(ORIGINAL, DESIGN, NA	ATIONAL STAGE OF PCT, CONTINUATION OR C-	SUPPLEMENTAL, DIVISIONAL, I-P)
As a below named invent	or, I hereby declare that:	
	TYPE OF DECLARAT	ION
This declaration is of the fo	llowing type:	
((check one applicable item	below)
onginal.		
design.		
supplemental.		
		eing filed as a divisional, continuation or check appropriate one of last three items.
national stage of	PCT.	
NOTE If one of the following 3 CONTINUATION OR C-	* * * * * * * * * * * * * * * * * * * *	so attach ADDED PAGES FOR DIVISIONAL,
divisional.		
continuation.		
Continuation-in-p	eart (C-I-P).	
IN	VENTORSHIP IDENTIF	ICATION
		claims, an explanation of the facts, including led invention was made, should be submitted.
I believe that I am the ongil	nal, first and sole inventor (eventor (if plural names are	as stated below, next to my name. If only one name is listed below) or listed below) of the subject matter the invention entitled:
	TITLE OF INVENTI	ON
Novel gene defective	ın apeced and its us	e ·

(Deciaration and Power of Attorney [1-1]-page 1 of 6)



SPECIFICATION IDENTIFICATION

the s	pec	of which.
		(complete (a), (b) or (c))
(a)	_	is attached hereto.
(b)	=	was filed on as _ Senal No. 0 / or _ Express Mail No., as Senal No. not yet known and was amended on (if applicable).
NOT		Amenaments filed after the original papers are deposited with the PTO that contain new matter an not accorded a filing date by being referred to in the declaration. Accordingly, the amendments involve are those filed with the application papers or, in the case of a supplemental declaration, are those amendments claiming matter not encompassed in the original statement of invention or claims. Set 37 CFR 1.67
(C)	X	was described and claimed in PCT International Application No PCT/F198/00749 filed on 23 Sept. 1998 and a
		amended under PCT Article 19 on (if any).
AC	K	OWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR
speci i ad	fica ckn	by state that I have reviewed and understand the contents of the above-identified atton, including the claims, as amended by any amendment referred to above, lowledge the duty to disclose information, which is material to patentability a in 37, Code of Federal Regulations, § 1.56,
		(also check the following items, if desired)
	_	and which is material to the examination of this application, namely, information

- where there is a substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent,
 - in compliance with this duty, there is attached an information disclosure statement, in accordance with 37 CFR 1.98.

PRIORITY CLAIM (35 U.S.C. § 119(a)-(d))

I hereby claim foreign priority benefits under Title 35. United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

(complete (d) or (e))

- (d) no such applications have been filed.
- (e) 💆 such applications have been filed as follows.
- NOTE Where item (c) is entered above and the international Application which designated the U.S. itself claimed priority check item (e), enter the details below and make the priority claim.

(Declaration and Power of Attorney [1-1]-page 2 of 6)



PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS APPLICATION AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. § 119(a)-(d)

COUNTRY (OR INDICATE IF PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 37 USC 119
FI	973762	23 Sept. 1997	™ YES NO □
			TYES NOT
			TYES NO T
			TYES NO T
			TYES NO T

CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S) (34 U.S.C. § 119(e))

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

PROVISIONAL APPLICATION NUMBER	FILING DATE
/	
/	
/	

CLAIM FOR BENEFIT OF EARLIER US/PCT APPLICATION(S) UNDER 35 U.S.C. 120

The claim for the benefit of any such applications are set forth in the
attached ADDED PAGES TO COMBINED DECLARATION AND POWER OF
ATTORNEY FOR DIVISIONAL, CONTINUATION OR CONTINUATION-IN
PART (C-I-P) APPLICATION.

(Declaration and Power of Attorney [1-1]-page 3 of 6)

	PREIGN APPLICATION(S), IF A 6 MONTHS FOR DESIGN) PRIC	NY, FILED MORE THAN 12 MONTHS OR TO THIS U.S. APPLICATION
	the basis for this application enten <mark>ng the Uniti</mark> divisional, or continuation-in-part, then also co	m the filing date of this application is a PCT filing forming ad States as (1) the national stage, or (2) a continuation, implete ADDED PAGES TO COMBINED DECLARATION U., CONTINUATION OR C-I-P APPLICATION for benefit 35 U.S.C. § 120.
	POWER OF	ATTORNEY
		and/or agent(s) to prosecute this application frademark Office connected therewith.
	(list name and reg	nistration number)
PAL	IL B WEST, 18947	PETER D. GALLOWAY, 27885
	EPH H. HANDELMAN, 26179	IAIN C. BAILLIE, 24090
	N RICHARDS, 31053	THOMAS F. PETERSON, 24790
	N J CHRYSTAL, 26360	RICHARD P. BERG, 28145
	HARD J STREIT. 25765	ЛЛІАН Н. COHEN, 20302 WILLIAM R. EVANS, 25858
	AN K. ROBERTS, 17777 DELVALLE GOLDSMITH, 14383	JANET I. CORD, 33778
3. L	DELVALLE GOLDSWITH, 14363	CLIFFORD J. MASS, 30086
	(check the following	g item, if applicable)
	Attached, as part of this declarate of the above-named attorney(s) representative(s).	on and power of attorney, is the authorization to accept and follow instructions from my
SEND C	ORRESPONDENCE TO	DIRECT TELEPHONE CALLS TO. (Name and telephone number)
ע	DAS & PARRY	
	WEST 61ST STREET	(212)708-1930
N	EW YORK, NEW YORK 10023	

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(Declaration and Power of Attorney [1-1]-page 4 of 6)



Attamey's Decket No. U 012653-9	PATENT
COMBINED DECLARATION AND POWER O	OF ATTORNEY
(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLI CONTINUATION OR C-I-P)	EMENTAL DIVISIONAL
As a below named inventor, I hereby declare that:	
TYPE OF DECLARATION	
This declaration is of the following type:	
(check one applicable item below)	
onginal.	
design.	
supplemental.	
NOTE If the declaration is for an international Application being filed continuation-in-part application, do not check next item; check application	
national stage of PCT.	
NOTE If one of the following 3 items apply, then complete and also attach CONTINUATION OR C-I-P	ADDED PAGES FOR DIVISIONAL.
divisional.	
continuation.	
continuation-in-part (C-I-P).	
INVENTORSHIP IDENTIFICATION	DN
WARNING: If the inventors are each not the inventors of all the claims, at the ownership of all the claims at the time the last claimed invent	,
My residence, post office address and citizenship are as stat I believe that I am the original, first and sole inventor (if only an original, first and joint inventor (if plural names are listed that is claimed, and for which a patent is sought on the inventor.)	one name is listed below) or below) of the subject matter
TITLE OF INVENTION	
Novel gene defective in apeced and its use	

(Declaration and Power of Attorney [1-1]-page 1 of 6)

SPECIFICATION IDENTIFICATION

th

the specification of which:
(complete (a), (b) or (c))
(a) Is attached hereto.
(b) was filed on as Serial No. 0 / or Express Mail No., as Serial No. not yet known and was amended on (if applicable).
NOTE Amendments filed after the original papers are deposited with the PTO that contain new matter are not accorded a filing date by being referred to in the declaration. Accordingly, the amendments involved are those filed with the application papers or, in the case of a supplemental declaration, are those amendments claiming matter not encompassed in the original statement of invention or claims. See 37 CFR 1.67.
(c) \overline{x} was described and claimed in PCT International Application No. PCT/F198/00749 filed on 23 Sept. 1998 and as amended under PCT Article 19 on (if any).
ACKNOWLEDGEMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR
I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.
I acknowledge the duty to disclose information, which is material to patentability as defined in 37. Code of Federal Regulations, § 1.56,
(also check the following items, if desired)
and which is material to the examination of this application, namely, information where there is a substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent, and
in compliance with this duty, there is attached an information disclosure statement, in accordance with 37 CFR 1.98.
PRIORITY CLAIM (35 U.S.C. § 119(a)-(d))
I hereby claim foreign priority benefits under Title 35. United States Code, § 119(a)–(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.
(complete (d) or (e))
(d) To no such applications have been filed.
(e) 🖄 such applications have been filed as follows.
NOTE Where item (c) is entered above and the International Application which designated the U.S. itself claimed priority check item (e), enter the details below and make the priority claim.

(Declaration and Power of Attorney [1-1]-page 2 of 6)

PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS APPLICATION AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. § 119(a)-(d)

COUNTRY (OR INDICATE IF PCT)	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 37 USC 119
FI	973762	23 Sept. 1997	☑ YES NO □
			TYES NOT
			TYES NO
			☐ YES NO ☐
			☐ YES NO ☐

CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S) (34 U.S.C. § 119(e))

I hereby claim	the benefit	under Titl	e 35.	United	States	Code,	§ 119(e)	of any	United
States provisiona	al application	n(s) listed	belov	v:					

PROVISIONAL APPLICATION NUMBER	FILING DATE
/	
/	

CLAIM FOR BENEFIT OF EARLIER US/PCT APPLICATION(S) UNDER 35 U.S.C. 120

_	The	claim	for	the	benefit	of a	any	such	applicati	ons	are	set	forth	ın	the
	atta	ched A	DDE	ED P	AGES T	0 C	OM	BINEC	DECLAR	RATIO	NC	AND	POW	ER	OF
	ATT	ORNE'	Y F	OR :	DIVISIO	NAL	, C	MITMO	NOITAUL	OR	CO	NTI	TAUN	ION	I-IN
	PAR	T (Cal	PI A	APPI	ICATIO	N									

(Declaration and Power of Attorney [1-1]-page 3 of 6)

 \rightarrow

NOTE. If the application filed more than 12 months from the filing date of this application is a PCT filing forming the basis for this application entering the United States as (1) the national stage, or (2) a continuation, divisional, or continuation-m-part, then also complete ADDED PAGES TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR DIVISIONAL, CONTINUATION OR C-I-P APPLICATION for benefit of the prior U.S. or PCT application(s) under 35 U.S.C. § 120. POWER OF ATTORNEY I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number) PAUL B WEST. 1894T PETER D. GALLOWAY, 27885 JOSEPH H. HANDELMAN, 26179 JOHN RICHARDS, 31053 THOMAS F. PETERSON, 24790 JOHN SCHARD J. STREIT. 25465 ALAN K. ROBERTS, 12277 WILLIAM R. EVANS, 26350 RICHARD P. BERG, 28145 JONET J. CORD, 33728. CLIFFORD J. MASS, 30086 (check the following item, if applicable) Attached, as part of this declaration and power of attorney, is the authorization of the above-named attorney(s) to accept and follow instructions from my representative(s) SEND CORRESPONDENCE TO DIRECT TELEPHONE CALLS TO. (Name and telephone number) LADAS & PARRY 26 WEST 61ST STREET NEW YORK, NEW YORK 10023			ANY, FILED MORE THAN 12 MONTHS OR TO THIS U.S. APPLICATION
I hereby appoint the following attomey(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number) PAUL B WEST. 18947 PETER D. GALLOWAY, 27885 JOSEPH H. HANDELMAN, 26179 IAIN C. BAILLIE, 24090 JOHN RICHARDS, 31053 THOMAS F. PETERSON, 24790 JOHN J CHRYSTAL, 26360 RICHARD P. BERG, 28145 RICHARD J STREIT, 25765 JULIAN H. COHEN, 20302 ALAN K ROBERTS, 17277 WILLIAM R. EVANS, 25858 S. DELVALLE GOLDSMITH, 14383 JANET I. CORD, 33778 CLIFFORD J. MASS, 30086 (cneck the following item, if applicable) Attached, as part of this declaration and power of attorney, is the authorization of the above-named attomey(s) to accept and follow instructions from my representative(s) SEND CORRESPONDENCE TO DIRECT TELEPHONE CALLS TO. (Name and telephone number)	the basis for this applica divisional, or continuatio AND POWER OF ATTO	tion entening the Un n-in-part, then also t RNEY FOR DIVISION	vited States as (1) the national stage, or (2) a continuation, complete ADDED PAGES TO COMBINED DECLARATION VAL, CONTINUATION OR C-I-P APPLICATION for benefit
And transact all business in the Patent and Trademark Office connected therewith. (list name and registration number) PAUL B WEST. 18947 PETER D. GALLOWAY, 27885 JOSEPH H. HANDELMAN, 26179 IAIN C. BAILLIE, 24090 JOHN RICHARDS, 31053 THOMAS F. PETERSON, 24790 JOHN J CHRYSTAL, 26360 RICHARD P. BERG, 28145 RICHARD J STREIT, 25765 JULIAN H. COHEN, 20302 ALAN K ROBERTS, 17277 WILLIAM R. EVANS, 25858 S. DELVALLE GOLDSMITH, 14383 JANET I. CORD, 33778. CLIFFORD J. MASS, 30086 (check the following item, if applicable) Attached, as part of this declaration and power of attorney, is the authorization of the above-named attorney(s) to accept and follow instructions from my representative(s) SEND CORRESPONDENCE TO DIRECT TELEPHONE CALLS TO. (Name and telephone number) LADAS & PARRY 26 WEST 61ST STREET		POWER OF	ATTORNEY
PAUL B WEST. 18947 JOSEPH H. HANDELMAN. 26179 JOHN RICHARDS. 31053 JOHN J CHRYSTAL. 26360 RICHARD P. BERG. 28145 RICHARD J STREIT. 25765 ALAN K ROBERTS. 17227 S. DELVALLE GOLDSMITH. 14383 Attached, as part of this declaration and power of attorney, is the authorization of the above-named attorney(s) to accept and follow instructions from my representative(s) PETER D. GALLOWAY, 27885 LAIN C. BAILLIE. 24090 RICHARD P. BERG. 28145 JULIAN H. COHEN. 20302 WILLIAM R. EVANS. 25858 CLIFFORD J. MASS. 30086 (check the following item, if applicable) Attached, as part of this declaration and power of attorney, is the authorization of the above-named attorney(s) to accept and follow instructions from my representative(s) SEND CORRESPONDENCE TO DIRECT TELEPHONE CALLS TO. (Name and telephone number) LADAS & PARRY 26 WEST 61ST STREET (712)708-1930			
JOSEPH H. HANDELMAN, 26179 JOHN RICHARDS, 31053 JOHN J CHRYSTAL, 26360 RICHARD P. BERG, 28145 RICHARD J STREIT, 25765 ALAN K ROBERTS, 17777 WILLIAM R. EVANS, 25858 S. DELVALLE GOLDSMITH, 14383 Geneck the following item, if applicable) Attached, as part of this declaration and power of attorney, is the authorization of the above-named attorney(s) to accept and follow instructions from my representative(s) SEND CORRESPONDENCE TO DIRECT TELEPHONE CALLS TO. (Name and telephone number) LADAS & PARRY 26 WEST 61ST STREET (712)708-1930	(list name and re	1
JOHN RICHARDS. 31053			
JOHN J CHRYSTAL. 26360 RICHARD P. BERG. 28145 RICHARD J STREIT. 25765 JULIAN H. COHEN. 20302 ALAN K ROBERTS. 17777 WILLIAM R. EVANS. 25858 S. DELVALLE GOLDSMITH. 14383 JANET I. CORD., 33778. CLIFFORD J. MASS. 30086 (check the following item, if applicable) Attached, as part of this declaration and power of attorney, is the authorization of the above-named attorney(s) to accept and follow instructions from my representative(s) SEND CORRESPONDENCE TO DIRECT TELEPHONE CALLS TO. (Name and telephone number) LADAS & PARRY 26 WEST 61ST STREET		And the second s	The state of the s
RICHARD J STREIT 25765 ALAN K ROBERTS, 17777 WILLIAM R. EVANS, 25858 S. DELVALLE GOLDSMITH, 14383 JANET I. CORD, 33778. CLIFFORD J. MASS, 30086 (check the following item, if applicable) Attached, as part of this declaration and power of attorney, is the authorization of the above-named attorney(s) to accept and follow instructions from my representative(s) SEND CORRESPONDENCE TO DIRECT TELEPHONE CALLS TO. (Name and telephone number) LADAS & PARRY 26 WEST 61ST STREET		-	
ALAN K ROBERTS, 1777 WILLIAM R. EVANS, 25858 S. DELVALLE GOLDSMITH, 14383 JANET I. CORD, 33778. CLIFFORD J. MASS, 30086 (check the following item, if applicable) Attached, as part of this declaration and power of attorney, is the authorization of the above-named attorney(s) to accept and follow instructions from my representative(s) SEND CORRESPONDENCE TO DIRECT TELEPHONE CALLS TO. (Name and telephone number) LADAS & PARRY 26 WEST 61ST STREET			
S. DELVALLE GOLDSMITH, 14383 JANET I. CORD, 33778. CLIFFORD J. MASS, 30086 (check the following item, if applicable) Attached, as part of this declaration and power of attorney, is the authorization of the above-named attorney(s) to accept and follow instructions from my representative(s) SEND CORRESPONDENCE TO DIRECT TELEPHONE CALLS TO. (Name and telephone number) LADAS & PARRY 26 WEST 61ST STREET			
(check the following item, if applicable) Attached, as part of this declaration and power of attorney, is the authorization of the above-named attorney(s) to accept and follow instructions from my representative(s) SEND CORRESPONDENCE TO DIRECT TELEPHONE CALLS TO. (Name and telephone number) LADAS & PARRY 26 WEST 61ST STREET			
Attached, as part of this declaration and power of attorney, is the authorization of the above-named attorney(s) to accept and follow instructions from my representative(s) SEND CORRESPONDENCE TO DIRECT TELEPHONE CALLS TO. (Name and telephone number) LADAS & PARRY 26 WEST 61ST STREET (712)708-1930			CLIFFORD J. MASS, 30086
of the above-named attorney(s) to accept and follow instructions from my representative(s) SEND CORRESPONDENCE TO DIRECT TELEPHONE CALLS TO. (Name and telephone number) LADAS & PARRY 26 WEST 61ST STREET (712)708-1930	(c	neck the following	ng item, if applicable)
[Name and telephone number] LADAS & PARRY 26 WEST 61ST STREET (212)708-1930	of the above-n	amed attorney(s	ition and power of attorney, is the authorization s) to accept and follow instructions from my
26 WEST 61ST STREET (212)708-1930	SEND CORRESPONDENCE 1	·o	• · · · · · · · · · · · · · · · · · · ·
(200), 50 6150	LADAS & PARRY		
			(212)708-1930

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(Declaration and Power of Attorney [1-1]-page 4 of 6)



SIGNATURE(S)

NOTE: Carefully indicate the family (or last) name, as it should appear on the filing receipt and all other documents.

Post Office Address Full name of second joint inventor, if any Maarit MONEN NAME Inventor's signature Date Country of Citizenship Residence Country of Citizenship	Heino FAMILY FOR LAST MAME) Finland
Post Office Address Full name of second joint inventor, if any Maarit GIVEN NAME Date Country of Citizenship Full name of second joint inventor, if any Maarit GIVEN NAME Country of Citizenship Residence Post Office Address	Heino FAMILY (OR LAST MAME) Finland
Full name of second joint inventor, if any Maarit MIDDLE INITIAL OR NAME) Inventor's signature Date Country of Citizenship Residence Post Office Address	Heino FAMILY (OR LAST MAME) Finland
Full name of second joint inventor, if any Maarit MIDDLE MITTAL OR NAME) Inventor's signature Date Country of Citizenship Residence Post Office Address	Heino FAMILY (OR LAST MAME) Finland
Full name of second joint inventor, if any Maarit MIDDLE INITIAL OR NAME) Inventor's signature Date Country of Citizenship Residence Post Office Address	Heino FAMILY (OR LAST MAME) Finland
Full name of second joint inventor, if any Maarit MIDDLE INITIAL OR NAME Inventor's signature Date Country of Citizenship Residence Post Office Address	FAMILY (OR LAST MAME)
Maarit (GIVEN NAME) (MIDDLE INITIAL OR NAME) Inventor's signature Date Country of Citizenship Residence Post Office Address	FAMILY (OR LAST MAME)
Inventor's signature Country of Citizenship Residence Post Office Address	FAMILY (OR LAST MAME)
Inventor's signature Country of Citizenship Residence Post Office Address	Inland
Date Country of Citizenship Residence Post Office Address	
ResidencePost Office Address	
ResidencePost Office Address	
-	
Full name of third joint inventor, if any	
Pärt	Peterson
(GIVEN NAME) (MIDDLE INITIAL OR NAME)	FAMILY FOR LAST NAME
Inventor's signature	
Date Country of Citizenship	Estonia
Residence	
Post Office Address	

(Declaration and Power of Attorney [1-1]-page 5 of 6)

(cneck proper box(es) for any of the following added page(s) that form a part of this declaration)

$\overline{\mathbf{x}}$	Signature for fourth and subsequent joint inventors. Number of pages added 2
	• • •
=	Signature by administrator(tnx), executor(tnx) or legal representative for deceased or incapacitated inventor. Number of pages added
	•••
=	Signature for inventor who refuses to sign or cannot be reached by person authorized under 37 CFR 1.47. Number of pages added
=	Added page for signature by one joint inventor on behalf of deceased inventor(s) where legal representative cannot be appointed in time. (37 CFR 1.47)
	• • •
=	Added pages to combined declaration and power of attorney for divisional, continuation, or continuation-in-part (C-I-P) application.
	Number of pages added
=	Authorization of attorney(s) to accept and follow instructions from representative.
	• • •
	(if no further pages form a part of this Declaration, then end this Declaration with this page and check the following item)
	This declaration ends with this page.

(Declaration and Power of Attorney [1-1]--page 6 of 6)

Attorney - Docker its		
		-
	TO COMBINED DECLARATION NATURE BY FOURTH AND SU	
Full name of fourth joint i	inventor, if any	
Hamısh		Scott
GIVEN NAME	MIDDLE INITIAL OR NAME	FAMILY (OR LAST NAME)
Date	Country of Citizenship	Australia
Residence		
Post Office Address		
Full name of fifth joint inv	ventor if any	
Stylianos	, on the time to t	Antonarakis .
GIVEN NAME	MIDDLE INITIAL OR NAME	FAMILY (OR LAST NAME)
Inventor's signature		
Date	Country of Citizenship _U	S/Greece
_	•	
Full name of sixth joint in	ventor, if any	
Marıa		Lalioti
GIVEN NAME	MIDDLE INITIAL OR NAME	FAMILY (OR LAST NAME)
nventor's signature		
Date	Country of Citizenship	
Residence		
Poet Office Address		

ADDED PAGE TO COMBINED DECLARATION AND POWER OF ATTORNEY FOR SIGNATURE BY FOURTH AND SUBSEQUENT INVENTORS

Full name of 7th joint in	ventor, ii ariy	
Nobuyoshi		Shimizu
GIVEN NAME	MIDDLE INITIAL OR NAME .	FAMILY FOR LAST NAME
Date	Country of Citizenship	Japan
Post Office Address		
	\$77422 FEBRUAR	
Full name of 8thjoint inve		-
·		Kudoh
JUN - GIVEN NAME	MIDDLE INITIAL OR NAME	FAMILY FOR LAST NAME
Inventor's signature		
-	Country of Citizenship	Japan
Full name of 9th joint inv	Water and the same of the same	-
Full name of 9th joint inv	Water and the same of the same	FAMILY (OR LAST NAM
	entor, if any	
GIVEN NAME Inventor's signature	entor, if any	
GIVEN NAME Inventor's signature Date	entor, if any MIDDLE INITIAL OR NAME	

5/9 FAX to - 3187-7050

Attorney's Docket No.	U 012653-9	
.*		
•		
	,	
ADDED PAGE TO	COMBINED DECLARATION	AND POWER OF
· · · · - - · ·	ATURE BY FOURTH AND SUB	-
7. dl	the many	
Full name of 7th joint in Nobuyoshi	ventor, ir any	Shimizu
GIVEN NAME	MIDDLE INITIAL OR NAME	FAMILY OF CAST NAME)
Inventor's signature 📿	Tobugohi Miciza	
Date May 5, 200/5	Country of Citizenship	Japan 💮
Residence 4-1-W21	03 Yukarigaoka, Saku	ra Chiba 285
Post Office Address	apan	
	7	
Full name of 8thjoint inve	entor, if any	a - Janes
Jun	·	Kudoh
GIVEN NAME	MIDDLE INITIAL OR NAME	FAMILY (OR LAST VAME)
nventor's signature	Jun Rudan	
Date May 8, 2000	Country of Citizenship	Japan
Residence 6-/4-2	8-303, Hon Komagiome, Bui	nkyo-ku, lokyo 113-002
Post Office Address	Japan	
Full name of 9th joint inv	entor, if any	
GIVEN NAME	MIDDLE INITIAL OR NAME	FAMILY (OR LAST NAME)
inventor's signature		
Date	Country of Citizenship	
Residence		
Post Office Address		

(Added Page to Combined Declaration and Power of Attorney for Signature by Fourth and Subsequent Inventors [1-2])